CONFIDENTIAL –FOIA Exemptions Apply in U.S. 1
Status: Approved ,  Date: [ADDRESS_493642] 2020Janssen Scientific and Medical Affairs*
Clinical Protocol
Protocol Title
A Phase 3b, Randomized, Double -blind, Multicenter Study to Evaluate the Safety and 
Efficacy of Intravenous Re- induction Therapy With Ustekinumab in Patients with 
Moderately to Severely Active Crohn’s Disease
Patient Optimization With ustEkinumab Re- induction (POWER)
Short Title
Efficacy and Safety of Ustekinumab Re -induction Therapy in Patients With
Moderately to Severely Active Crohn’s Disease With Secondary Loss of Response
Protocol CNTO1275CRD3008 ; Phase 3b
AMENDMENT 4
STELARA (ustekinumab)
*Janssen Scientific and Medical Affairs is an organization that operates through different legal entities in
various countries. The legal entity acting as the sponsor for Janssen Scientific and Medical Affairs studies
may vary, such as bu t not limited to :Janssen Scientific Affairs, LLC; Janssen Biologics BV ;Janssen- Cilag
International NV; or Janssen Pharmaceutica NV. The term ‘sponsor’ is used throughout the protocol to
represent these various legal entities; the sponsor is identified onthe Contact [CONTACT_369051].
EudraCT NUMBER: 2018 -002629 -51
Status: Approved
Date: [ADDRESS_493643] 2020
Prepared by: [CONTACT_48873]- Cilag Ltd.
EDMS number :EDMS- ERI-156184811, 10.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice and applicable regulatory 
requirements.
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and 
may not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed
by [CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as 
privileged or confidential.
[STUDY_ID_REMOVED]
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 2
Approved , Date: [ADDRESS_493644] 2020
Amendment 3 19 May 2020
Amendment 2 8April 2020 (COVID -19 amendment)
Amendment [ADDRESS_493645] 2020
Overall Rationale for the Amendment: To increase enrollment into the study, through allowing patients 
who have previously received a dose interval shortening of 90mg SC ustekinumab less than every 8 weeks
and clarify ileocolonoscopy as an exploratory endpoint for participants who agree to this procedure .
Section Number
and Nam e Description of Changes and Brief Rationale
5.1 Inclusio n Criteria OR 5.2 
Exclusion Criteria; 
10.2 Definition of 
Ustekinumab Initial 
Response and Current 
Therapy.Description of Change: Allowed for inclusion of patients who have previously 
received a dose interval shortening of [ADDRESS_493646] since received specified per label doses.
Evidence of prior ustekinumab treatment and response/remission should be 
documented by [CONTACT_30219], if available. If such document ation is 
unavailable, the investiga tor can confirm the ustekinumab doses, and initial 
response/remission in the eCRF to the irbest knowledge and clinical judgement. 
Rationale: To enable recruitment of patients.
Synopsis; 9.5 Interim 
Analyses .Description of Change: Included an overview of interim analys is to test for 
futility.
Rationale:
To test for futility and assess/confirm sample size.
Synopsis; 1.3Schedule of 
Activities; 3 Objectives and 
Endpoints; 4.1 Overall 
Design ; 8Study Assessments 
and ProceduresDescription of Change: Clarified that ileocolonoscopy should be performed 
only at the physician’s discretion and where participants agree for this 
procedure , for evaluation of this exploratory endpoint .Where this is not 
performed, this will not be considered a protocol deviatio n.
Rationale: To enable recruitment and patient retention.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 3
Approved , Date: [ADDRESS_493647] OF IN -TEXT T ABLES A ND FIGURES ................................................................................................ 5
1. PROTOCOL SUMMA RY..................................................................................................................... 6
1.1. Synopsis ........................................................................................................................................... 6
1.2. Schema .......................................................................................................................................... 11
1.3. Schedule of Activities ..................................................................................................................... 12
2. INTRODUCTION ................................................................................................................................ 16
2.1. Study Rationale .............................................................................................................................. 16
2.2. Background .................................................................................................................................... 17
2.2.1. Development of the Current Ustekinumab Dosing Regimen in Crohn’s Disease ...................... 17
2.2.2. Loss of Res ponse to Ustekinumab Maintenance Dosing ........................................................... 18
2.2.3. Dose Adjustment in Patients with Loss of Response to Ustekinumab ....................................... 19
2.3. Benefit/Risk Assessment ............................................................................................................... 20
3. OBJECTIVES A ND ENDPO INTS ..................................................................................................... 22
4. STUDY DESIGN ................................................................................................................................ 25
4.1. Overall Design ................................................................................................................................ 25
4.2. Scientific Rationale for Study Design ............................................................................................. 26
4.2.1. Study-Specific Ethical Design Considerations ........................................................................... 27
4.3. Justification for Dose ...................................................................................................................... 28
4.4. End of Study Definition ................................................................................................................... 29
5. STUDY POPUL ATION...................................................................................................................... 29
5.1. Inclusion Criteria ............................................................................................................................ 29
5.2. Exclusion Criteria ........................................................................................................................... 32
5.3. Lifestyle Considerations ................................................................................................................. 36
5.4. Screen Failures .............................................................................................................................. 36
6. STUDY INTERVENTION ................................................................................................................... 37
6.1. Study Interventions Administered .................................................................................................. 37
6.2. Preparation/Handling/Storage/Accountability ................................................................................ 38
6.2.1. Storage and Preparation ............................................................................................................. 38
6.2.2. Drug Accountability ..................................................................................................................... 39
6.3. Measures to Minimize Bias: Randomization and Blinding ............................................................. 39
6.4. Study Intervention Compliance ...................................................................................................... 41
6.5. Concomitant Therapy ..................................................................................................................... 41
6.5.1. Crohn’s Disease -specific Concomitant Medications .................................................................. 41
6.5.2. Oral Corticosteroids .................................................................................................................... 42
6.5.3. Prohibited Medications ............................................................................................................... 42
6.6. Dose Modification ........................................................................................................................... 43
6.7. Intervention After the End of the Study .......................................................................................... 43
7. DISCONTINUA TION OF S TUDY INTERVENTION A ND PA RTICI PANT 
DISCONTINUA TION OR W ITHDRA WAL......................................................................................... 43
7.1. Discontinuation of Study Intervention ............................................................................................ 43
7.2. Participant Discontinuation/W ithdrawal From the Study ................................................................ [ADDRESS_493648] to Follow -up............................................................................................................................ 46
8. STUDY A SSESSMENTS AN D PROCEDURES ............................................................................... 46
8.1. Efficacy  Assessments .................................................................................................................... 47
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 4
Approved , Date: [ADDRESS_493649] [ZIP_CODE].1.1. Overview ..................................................................................................................................... 47
8.1.2. Crohn’s Disease Activity Index ................................................................................................... 48
8.1.3. C-reactive Protein ....................................................................................................................... 48
8.1.4. Calprotectin ................................................................................................................................ .49
8.1.5. Inflammatory  Bowel Disease Questionnaire ............................................................................... 49
8.1.6. Fistula Assessment ..................................................................................................................... 49
8.1.7. Video Ileocolonoscopy ................................................................................................................ 49
8.2. Safety Assessments ....................................................................................................................... 50
8.2.1. Physical Examination .................................................................................................................. 50
8.2.2. Vital Signs ................................................................................................................................... 50
8.2.3. Clinical Safety Laborator y Assessments .................................................................................... 51
8.3. Adverse Events and Serious Adverse Events ............................................................................... 51
8.3.1. Time Period and Frequency for Collecting Ad verse Event and Serious Adverse Event 
Information .................................................................................................................................. 52
8.3.2. Method of Detecting Adverse Events and Serious Adverse Events .......................................... 52
8.3.3. Follow -up of Adverse Events and Serious Adverse Events ....................................................... 52
8.3.4. Regulatory Reporting Requirements for Serious Adverse Events ............................................. 52
8.3.5. Pregnancy ................................................................................................................................... 53
8.3.6. Infusion/Injection Site Reactions and Allergic Reactions ........................................................... 53
8.3.7. Infections .................................................................................................................................... 54
8.3.8. Malignancies ............................................................................................................................... 54
8.3.9. Disease -Related Events and Disease -Related Outcomes Not Qualifying as Adverse 
Events or Serious Adverse Events ............................................................................................. 54
8.4. Treatment of Overdose .................................................................................................................. 54
8.5. Pharmacokinetics and Immunogenicity ......................................................................................... 55
8.5.1. Evaluations ................................................................................................................................ .55
8.5.2. Analytical Procedures ................................................................................................................. 55
8.5.3. Pharmacokinetic Parameters and Evaluations ........................................................................... 55
8.6. Genetics ......................................................................................................................................... 55
8.7. Medical Resource Utilization and Health Economics .................................................................... 55
8.8. Biom arkers ..................................................................................................................................... 56
8.8.1. Serum -based Biomarkers ........................................................................................................... 56
8.8.2. Whole Blood- based Biomarkers ................................................................................................ .56
9. STATISTICA L CONSIDER ATIONS .................................................................................................. 56
9.1. Statistical Hypothesis ..................................................................................................................... 56
9.2. Sample Size Determination ........................................................................................................... 57
9.3. Populations for Analy sis................................................................................................................. 57
9.4. Statistical Analysis ......................................................................................................................... 57
9.4.1. Efficacy  Analysis ......................................................................................................................... 57
9.4.2. Safety Analysis ........................................................................................................................... 58
9.4.3. Other Analyses ........................................................................................................................... 59
9.5. Interim Analysis .............................................................................................................................. 60
10. SUPPORTING DOCUMENT ATION A ND OPERA TIONA LCONSIDERA TIONS ............................ 61
10.1. Appendix 1: Abbreviations and Definition of Terms ....................................................................... 61
10.2. Appendix 2: Definition of Ustekinumab Initial Response and Current Therapy ............................. 62
10.3. Appendix 3: Tuberculin Skin Testing ............................................................................................. 64
10.4. Appendix 4: Anticipated Events ..................................................................................................... 66
10.5. Appendix 5: Clinical Laboratory Tests ........................................................................................... 67
10.6. Appendix 6: Regulatory, Ethical, and Study Oversight Considerations ......................................... 68
10.7. Appendix 7: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting ............................................................................................................... 79
10.8. Appendix 8: Contraceptive and Barrier Guidance and Collection of Pregnancy Information ........ 84
10.9. Appendix 9: Protocol Amendment History ..................................................................................... 87
10.10. Appendix 10: Sample Crohn’s Disease Activity Index ................................................................... 90
10.11. Appendix 11: CDAI Standard Weight Table ................................................................................... 91
10.12. Appendix 12: Sample Inflammatory  Bowel Disease Questionnaire .............................................. 93
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 5
Approved , Date: [ADDRESS_493650] 202010.13. Appendix 13: Guidance o n Study Conduct during the COVID -[ADDRESS_493651] OF IN -TEXT TA BLES A ND FIGURES
TABLES
Table 1: Recommended Tapering Schedule for Oral Corticosteroids .................................................... 42
Table 2: Power to Detect a Treatment Effect Based on Different Proportions of Participants 
Achieving Clinical Response at W eek 16 (Each Group) .......................................................... 57
Table 3: Populations for Analy sis............................................................................................................ 57
FIGURES
Figure 1:Study Designs for the Ustekinumab Phase 3 Development Program in Crohn’s 
Disease ..................................................................................................................................... 18
Figure 2:Minimum Required Time Windows Between Administration of Study Intervention (IV 
or SC ) at Week0...................................................................................................................... 37
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 6
Approved , Date: [ADDRESS_493652] [ZIP_CODE]. PROTOCOL SUMMARY
1.1. Synopsis
A Phase 3b, Randomized, Double -blind, Multicenter Study to Evaluate the Safety and Efficacy of 
Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely 
Active Crohn’s Disease
Ustekinumab is a fully human immunoglobulin G1 kappa (IgG1k) monoclonal antibody to human 
IL-12/23p40 that binds with high affinity to human IL-12 and IL-23. Ustekinumab prevents IL-12 and 
IL-23 bioactivity by [CONTACT_393376]-12Rβ1 receptor protein, thereby 
[CONTACT_393377]-12 (Th1) and IL-23 (Th17) mediated cellular responses. Abnormal regulation 
of IL-12 and IL-23 has been associated with multiple immune -mediated diseases, including psoriasis, 
psoriatic arthritis, and inflammatory bowel disease. By [CONTACT_209767] p40 subunit of IL -12 and IL -23, 
ustekinumab may exert its clinical effects through interruption of the Th1 and Th17 cytokine pathways, 
which are central to the pathology of these diseases.
OBJECTIVES AND ENDPOINTS
Objective s
The primary objective is to evaluate the achievement of clinical response at Week 16 following a single IV 
re-induction dose of 6mg/kg ustekinumab, compared with continuing regular SC q8w 90mg ustekinumab 
administration, in participants with secondary loss of response (LoR)to SC q8w 90mg ustekinumab 
maintenance therapy.
The secondary objectives are to:
 Evaluate the achievement of clinical response and clinical remission, as well as the reduction in 
inflammatory biomarkers (serum C-reactive protein [CRP ] and fecal calprotectin [fCal] levels) ,after 
IV ustekinumab re -induction.
 Assess the overall safety of IV ustekinumab re -induction.
Other objectives are toassess endoscopy and patient -reported assessment of bowel inflammation following
IV ustekinumab re-induction, and to assess the steroid -sparing effect and pharmacokinetics following a 
single IV re -induction dose of 6 mg/kg ustekinumab.
Endpoints
The primary endpoint is clinical response at Week 16, defined as a ≥100 -point reduction from the baselin e 
Crohn’s Disease Activity Index (CDAI) score or a CDAI score <150 points.
The maj or secondary endpoints, listed in order of testing, are as specified below:
 Clinical remission at Week 16, defined as a CDAI score of <150 points.
 Clinical response at Week 8, defined as a ≥100 -point reduction from the baseline CDAI score or a 
CDAI score <150.
 Clinical remission at Week 8, defined as a CDAI score of <150 points.
 Normalization of CRP and/or fCal concentration(s) at Week 16,among participants with eleva ted CRP 
and/or fCal at baseline.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 7
Approved , Date: [ADDRESS_493653] 2020Other secondary endpoints are:
 Clinical remission at Week 24, defined as a CDA I score of <150 points.
 Clinical response at Week 24, defined as a ≥100 -point reduction from the baseline CDAI score or a 
CDAI score <150.
 Normalization of CRP and/or fCal concentration(s) at Week 24,among participants with elevated CRP 
and/or fCal at baseline.
 Safety endpoints, includ ingthe proportion of participants with at least one adverse event and 
subcategories of adverse events (all infections, all serious adverse events and serious infections), as 
well as changes in clinical laboratory test results .
Other endpoints are described in Section 3of the protocol.
Hypothesis
The study hypothesis is that in patients with secondary LoR to SC q8w 90 mg ustekinumab maintenance 
treatment, a single weight -tiered based IV ustekinumab re-induction dose of 6mg/kg 
(ie,IVustekinumab /SC placebo at Week 0) followed by q8w 90 mg ustekinumab maintenance will result 
in a higher clinical response rate (defined as a ≥100 -point reduction from the baseline CDAI score, or a 
CDAI score <150) compared with continuous SC q8w 90 mg ustekinumab maintenance treatment
(ie,IVplacebo /SC ustekinumab at Week 0) after 16 weeks .
OVERALL DESIGN
This is a randomized, double -blind, placebo -controlled, multicenter, 24-week, Phase 3b study in adult 
patients with moderate lyto severe lyactive Crohn’s disease who initially responded (as defined in 
Section 10.2, Appendix 2of the protocol ) to ustekinumab induction therapy per label followed, at any time, 
by [CONTACT_393378] q8w ustekinumab maintenance therapy. The benefit of a single weight -tiered based 
IV re-induction dose of 6mg/kg body weight ustekinumab versus continuous SC q8w maintenance 
treatment will be evaluated.
Secondary LoR is defined as a CDAI score of 220 and ≤[ADDRESS_493654] one of thefollowing:
 Elevated CRP (>3.0 mg/L); and/or
 Elevated fCal (>250 mg/kg); and/or
 Endoscopy (ileocolonoscopy ) performed ≤3months before baseline with evidence of active Crohn’s 
disease ( defined as one or more ulcerations in the ileum and/or colon).
Eligible participants will be randomly assigned to 1of the following 2intervention group s in a 1:1ratio,
using permuted block randomization stratified at the study level by [CONTACT_3445]’s baseline CDAI score 
(≤300 or >300) and prior biologic failure (yes or no) at baseline :
 Ustekinumab re -induction: IV ustek inumab and SC placebo at Week 0.
 Continuous maintenance: IV placebo and SC ustekinumab at Week 0.
At baseline (Week 0), approximately 8weeks (±2weeks) after the previous per label dose of SC 90mg 
ustekinumab maintenance, participants will undergo clinical assessments. Following randomization, 
participants will receive either IV ustekinumab 6mg/kg and SC placebo or IV placebo and SC 
ustekinumab 90 mg in a doub le-blind manner (IV administration will be as an infusion and SC 
administration will be as an injection) .Either the IV infusion or the SC injection may be administered first 
at Week 0, based on the standard-of- care practices at the study site; there must be no concurrent 
administration of IV and SC study intervention .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 8
Approved , Date: [ADDRESS_493655] study intervention administration (ie,Week 36 for participants who 
complete the final study intervention visit at Week 16); this may be conducted at a site visit or by [CONTACT_756].
A participant will be considered to have completed the study if he/she h as completed assessments through 
the 24-week treatment period and the Week [ADDRESS_493656] completed the study assessments through 
Week 16 (or at an early termination visit). The end of study is considered the last scheduled study 
assessment for the last participant in the study.
Key efficacy assessments will include clinical response (CDAI reduction ≥100), clinical remission (CDAI 
value <150) and biomarker normalization. Safety assessments will include the monitoring of adverse 
events, vital signs, and clinical laboratory tests.
NUMBER OF PARTICIPANTS
The study will include approximately 200 participants , with approximately 100 participants in each o f the 
2intervention group s.
INTERVENTION GROUPS AND DUR ATION
Administration of Interventions
Study intervention will start at baseline (Week 0), approximately 8weeks (±2weeks) after the previous 
dose of per label SC 90mg ustekinumab maintenance treatment. The date of the previous dose of 
ustekinumab will be recorded in the case report form (CRF).
To maintain the double- blind, at Week 0 all participants will receive one IV infusion of study intervention 
(ustekinumab 6mg/kg or placebo) plus one SC administration of study intervention (ustekinumab 90 mg 
or placebo).
At Week [ADDRESS_493657] -of-care therapy with 
either ustekinumab maintenance therapy per label or another treatment modality at the discretion of their 
physician.
Description of Interventions
Study intervention should be dispensed under the supervision of the in vestigator ,a qualified member of the 
study -site personnel, or by a hospi[INVESTIGATOR_307]/clinic pharmacist. Study intervention in glass vials and PFS will be 
ready to use. The required volume of study intervention will be prepared using the appropriate vials or PFS.
Aseptic procedures must be used during the preparation and administration of the ustekinumab solution for 
IV infusion.
For IV administration, the study intervention will be administered to each participant as an infusion o ver a 
period of not less than 1hour by [CONTACT_3436]. The infusion should be completed within 8hours of 
preparation. Details of each infusion will be recorded in the CRF (including date, start and stop times of the 
IV infusion, and volume infused).
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 9
Approved , Date: [ADDRESS_493658] 
received the requi red training to perform self-administration of SC injections. Details of each administration 
will be recorded in the CRF (including date and time of administration).
EFFICACY EVALUATIONS
Efficacy evaluations will include the following:
 CDAI (the primary to ol for assessing disease activity response to ustekinumab) .
 PRO -2 (the CDAI components of the total number of liquid or very soft stools and the abdominal pain 
score) .
 Inflammatory Bowel Disease Questionnaire (IBDQ) .
 Inflammatory markers including serum CR P and fCal .
 Fistula assessment .
 Endoscopic assessments of the intestinal mucosa based on the presence and absence of mucosal 
ulcerations and the SES -CDin the subset of patients with endoscopi[INVESTIGATOR_393357] .
Other endpoints are described in Section 3of the protocol .
PHARMACOKINETIC AND IMMUNOGENICITY EVALUATIONS
Serum samples will be used toevaluate the PK of ustekinumab and to detect and characteriz e
anti-ustekinumab antibodies. Serum collected for PK and immunogenicity evaluations may additionally be 
used to explore safety or efficacy aspects arising during or after the study period.
The blood sample for trough serum PK must be collected at all study visits prior to the administration of 
ANY study intervention (ie, IV or SC ustekinumab) as well as prior to the administration of standard-of-
care therapy at Week 24. The post -IV infusion PK blood sample at Week 0 should be drawn approximately 
60minutes after completion of the IV infusion.
BIOMARKERS
Biomarker assessments will be conducted to examine the biologic response to treatment and to identify 
biomarkers that are relevant to ustekinumab treatment and/or Crohn’s disease. Assessments may include 
the evaluation of relevant biomarkers in serum, blood, and/or stool samples collected as specified in the 
Schedule of Activities. Data collected from these samples will be used for exploratory research purposes .
SAFETY EVALUATIONS
Safety will be assessed through Week [ADDRESS_493659] study intervention administration (ie, Week 36 
for participants who complete the final study intervention visit at Week 16).
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 10
Approved , Date: [ADDRESS_493660] 2020STATISTICAL METHODS
The assumptions that form the basis for sample size and power calculations incorporated into this protocol 
to support the primary endpoint are based on the dose adjustment data from the IMUNIT I Phase 3 study. 
In IMUNIT I, 17 of 29 (59%) participants attained clinical response 16weeks after LoR in the q12w adjusted 
to q8w group, while 11 of 28 (39%) participants attained clinical res ponse 16 weeks after LoR in the sham 
dose adjustment group (ie. continually remaining on SC q8w dosing). The hypothesis for the sample size 
determination is that the IV ustekinumab group in this study will perform similarly to, if not better than, the 
q12w adjusted to q8w group in the IMUNITI study, given that the participants in this group will receive a 
higher dose of ustekinumab than those in the IMUNITI study, who received an adjustment from q12w to 
q8w.
Assuming a 60% clinical response rate at Week 16 in the IV ustekinumab group and 40% in the continuous 
SC q8w 90mg group, 100 participants per intervention group will yield an overall power above 80%, at a
significance level of 0.05 (2- sided, Mantel -Haenszel test ).
Efficacy analyses will be based on a n intent -to-treat principle; the efficacy data for each participant will be 
analyzed according to the assigned treatment regardless of the actual treatment received.
For the primary endpoint, the proportion of participants in clinical response at Week [ADDRESS_493661], stratified by [CONTACT_393379] (≤300 or >300) and prior biologic failure status 
at baseline (yes or no) at a signif icance level of 0.05.
Participants with missing data, defined as those participants who terminate the study before the designated 
visit or participants who have (a)missing value (s)at the designated visit, will be considered to not have 
achieved their dichotomous efficacy endpoints. For continuous endpoints, the last available value will be 
carried forward for participants with missing data.
Treatment failure rules will override the response status (eg, clinical response, clinical remission, and 
mucosal healing). Participants who meet any of the following criteria for treatment failure will be 
considered to not have achieved their dichotomous efficacy endpoints from the time the treatment failure 
occurs onwards:
 Had a Crohn’s disease -related surgery due to lack of efficacy; OR
 Discontinued study intervention due to an adverse event of worsening Crohn’s disease or due to lack 
of efficacy; OR
 Had a prohibited change in concomitant medications (to be detailed in the statistical analysis plan).
For continuous efficacy endpoints, the baseline value will be carried forward from the time the treatment 
failure occurs onwards.
Aninterim analys is will be performed in the study to test for futility after [ADDRESS_493662] 
completed the efficacy assessment at Week 16,and to assess sample size.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 11
Approved , Date: [ADDRESS_493663] [ZIP_CODE].2. Schema
C=clinical assessment; E=endoscopy (where applicable) ;IV=intravenous (infusion) ; LoR=Loss of response; PBO=Placebo; PE=primary endpoint; 
PK=pharmacokinetic sampling (for immunogenicity + ustekinumab concentration); q8w=dosing every 8 weeks; R=ra ndomization; SC=subcutaneous (injection) ; 
SOC=Standard of care (participants will resume their standard -of-care therapy after study assessments at Week 24); UST=ustekinumab; BW=body weight .
Follow -up for evaluation of safety approximately [ADDRESS_493664] study intervention administration (ie, Week 36 for participants who complete the final study 
intervention visit at Week 16)may be conducted at a site visit or by [CONTACT_756].

STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 15
Approved , Date: [ADDRESS_493665] 2020Footnotes:
a. Visit window  should be ±4 days for each visit up to and including Week 16 and ±[ADDRESS_493666] study intervention administration ; for participants who complete the final 
study intervention visit at Week 16, this will occur at Week 36 . The safety follow up may be conducted at a site visit or by [CONTACT_393380],
including those who discontinued study intervention before Week 24 or otherw ise terminated study participation (eg, through withdraw al of consent), unless they 
do not consent to this follow  up by  [CONTACT_3449] -site staff.
c. Stool test for enteric pathogens must include a stool culture and C. difficile toxin assay performed within 4 months before Week 0. Additional testing may be 
performed at the investigator’s discretion.
d. Screening for HBV to include HBsAg, anti -HBs, and anti -HBc. Participants are eligible if they are: 1) negative for these tests OR 2) negative for HBsAg; positive 
only for anti -HBs; or positive for anti -HBc and surface antibody OR 3) positive only for anti -HBc, bu t with a negative HBV DNA test.
HIV antibody test need not be performed if a negative result in last [ADDRESS_493667] received requi red training may self -administer SC 
study intervention at Week 8 and/or Week 16.
f. Clinical laboratory tests for assessment of screening criteria and for study evaluations are further described in Section 10.5, Appendix 5of the protocol.
g. The IBDQ at the early terminati on visit is required only for participants who did not remain in the study at Week 16(due to early discontinuation of study 
intervention and/or early termination of study participation) or did not perform the IBDQ at Week 16.
h. All reasonable attempts shoul d be made to collect samples at the scheduled timepoints and record the actual times of PK sample collections.
At each time point, one venous blood sample of sufficient volume should be collected. Each serum sample will be divided into 3 aliquots (for uste kinumab serum 
concentration, antibody assessment, and a back -up), except for the post -infusion blood sample at Week 0 which will be for PK evaluation only.
Determination of ustekinumab serum concentrations and antibody assessments will be performed by a ce ntral laboratory.
CDAI=Crohn’s Disease Activity Index; CRP=C -reactive protein ; HBV=hepatitis B virus; HCV=hepatitis C virus; HIV=human immunodeficiency virus ; 
IV=intravenous ; PK=pharmacokinetic .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 16
Approved , Date: [ADDRESS_493668] [ZIP_CODE]. INTRODUCTION
Ustekinumab is a fully  human immunoglobulin G1 kappa (IgG1k) monoclonal antibody  to human 
IL-12/23p40 that binds with high affinit y to human IL -12 and IL -23. Ustekinumab prevents IL -12 
and IL-23 bioactivity  by [CONTACT_393381]-12Rβ1 receptor 
protein, thereb y effectively  neutraliz ingall IL-12 (Th1) and IL-23 (Th17) mediated cellular 
responses. Abnormal regulation of IL-[ADDRESS_493669] s, which are central to the pathology 
of these diseases.
STEL ARA®(ustekinumab)27was initially  approved for the treatment of adults with moderate to 
severe chronic plaque psoriasis in the European Union (EU) in January  2009 and in the United 
States (US) in September 2009, and gained subsequent approvals for psoriatic arthritis and
adolescent psoriasis, followed by [CONTACT_393382] y to 
severel y active Crohn’s disease on [ADDRESS_493670] version of the Investigator’s Brochure for STEL ARA (ustekinumab ).
The term ‘ study  intervention ’used throughout this document refers to ustekinumab administered 
as a6mg/kg intravenous ( IV)infusion or as a 90mgsubcutaneous ( SC)injection .
The term ‘sponsor’ used throughout this document refers to the entities listed in the Contact 
[CONTACT_23774](s), which will be provided as a separate document.
2.1. Study Rationale
Crohn’s disease is a chronic debilitating inflammatory  disease of the digestive tract with a 
remitting and relapsing course. For the last decade, Crohn’s disease has been most effectivel y 
treated with monoclonal antibodies to tumo rnecrosis factor (TNF ); however, approximately 
one-third of patients do not respond to anti -TNFs initially , and a further third lose response during 
theircourse of treatment, requiring dose adjustment or switch to another medication .16There is a 
significant medical need for new safe and effective therapi[INVESTIGATOR_393358], active Crohn’s 
disease as well as to optimize the limited treatment options currently  available.
Theapproved dosing regimen for ustekinumab in the treatment of Crohn’s disease compris es an 
initial weight -tiered based induction dose of approximately  6mgustekinumab per kg body  weight 
(6mg/kg)administered intravenousl y followed by[CONTACT_102052] 90mg administered 
subcutaneousl y from Week 8. In the EU, the approved maintenance dosing regimen is 90mg SC 
every  12weeks (q12w) after Week 8, although patients who have not demonstrated an adequate 
response at Week 16 or who subsequently  lose response may be dosed every  8weeks (q8w). In 
the US, patients receive maintenance doses of 90 mg SC q8w from Week 8per label .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 17
Approved , Date: [ADDRESS_493671] 2020While the clinical development program for ustekinumab established that both of theapproved 
maintenance doses maintained clinical response through Week 44 (Section 2.2.1 ), it was 
demonstrated that a proportion of patients on maintenance dosing with ustekinumab will lose their 
response over time (Section 2.2.2 ). In a proportion of patients, the loss of response (LoR)to 
ustekinumab maintenance treatment isassociated with low serum levels of ustekinumab 
(Section 2.2.3 ).Patients commonly  lose response to biologics for the treatment of Crohn’s disease , 
requiring dose intensification to regain response.20Similarly , patients in the EU with LoR toq12w 
maintenance dosing with ustekinumab may regain the response following dose adjustment to q8w 
maintenance dosing. However, there is no option for dose adjustment for patients in the US or EU 
who have lost response to q8w maintenance dosing. It is expected that a proportion of patients
with LoR to q8w maintenance dosing will regain response employ inga strategy of increasing 
serum concentrations .The approved IV dose provides a logical option to rapi[INVESTIGATOR_393359].
The aim of this study  is to demonstrate the efficacy of a single weight -tiered based ustekinumab 
IV re-induction dose of 6mg/kgversus continuous ustekinumab S C maintenance treatment in 
adult patients with moderate lyto severe lyactive Crohn’ s disease demonstrating a secondary  LoR
to ustekinumab q8w maintenance treatment.
2.2. Background
2.2.1. Development of the Current Ustekinumab Dosing Regimen in Crohn’s 
Disease
The Phase 3 development program for ustekinumab in Crohn’s disease consisted of three Phase 3 
trials: two 8-week induction studies (CNTO1275CRD3001 [ UNITI-1] and CNTO1275CRD3002 
[UNITI-2])that fed into one 44-week maintenance study (CNTO1275CRD3003 [ IMUNIT I]) 
(Figure 1).
Participant s in the UNITI-1andUNIT I-2studies who met the criteria for clinical response to IV 
induction with ustekinumab at Week 8 (defined as a reduction from baseline in CDAI score 
100points or total CDAI score <150 points) were randomized to receive either placebo 
maintenance or ustekinumab maintenance of q8w or q12w through Week 40 in the IMUNIT I 
study , in which the primary  endpoint was clinical remission at Week 44 (CDAI<150). The 
IMUNITI protocol allowed for blinded crossover to dose escalation f or participant s who qualified 
due to LoR; participants with LoR on placebo maintenance or q12w ustekinumab maintenance 
were switched to q8w ustekinumab maintenance , while participants with LoR on q8w maintenance 
received a sham dose escalation of continued q8w maintenance.
Based on the results of these studies, a weight -tiered based IV dose of  6mg/kg body  weight was 
selected as the approved induction dose and [ADDRESS_493672] not shown adequate response at Week 16or who subsequently  lose response 
may be switched to q8w maintenance dosing .Indeed, theflexibility  to optimize results is 
recognized as an important option in the treatment of Crohn’s disease .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 18
Approved , Date: [ADDRESS_493673] 2020Figure 1: Study Design sfor the Ustekinumab Phase 3 Development Program  in Crohn’s Disease
*Conventional therapy is defined as corticosteroids and/or immunomodulator. IV=intravenous; LTE= long-term 
extension, q8w =every 8 w eeks; q12w =every 12 w eeks; SC=subcutaneous; TNF =Tum ornecrosis factor; 
PE=primary endpoint; SE =secondary endpoint ; UST=ustekinumab
2.2.2. Loss of Response to Ustekinumab Maintenance Dosing
While the results of the IMUNIT I study  established that both the q12w and q8w doses of 
ustekinumab maintenance therap y were superior to placebo and maintained clinical response 
through Week 44, by[CONTACT_10585] 32 approximately  20% of participants in each ustekinumab 
maintenance arm met the criteria for dose escalation due to LoR (defined as CDAI  ≥220 points 
and an increase in CDAI score from baseline of maintenance of ≥100 points).9Of those who 
entered the long-term extension , an additional approximate ly10% were nolonger in response by 
[CONTACT_10585] 92.21The results were similar between the 2maintenance dosing regimens at both 
timepoints.
Theobservation of patients losing response over time has been observed with all biologics in the 
treatm ent of Crohn’s disease , including 3TNF inhibitors1,5,13and a n integrin receptor antagonist29. 
A recent s ystematic review and meta -analysis of 86 studies of patients with Crohn’s disease found 
that approximately 30% of primary  anti-TNF responders experienced a LoR and required dose 
adjustment to regain and maintain response
.20Rates of LoR after up to 1year of treatment with 
vedolizumab have been reported to be around 50% in normal clinical practice .3,26
Considerable research has been conducted on the reasons for patients losing their initial respons e 
to biologic therap y. The causes for LoR, known as secondary  nonresponse, fall into 2general 
categories8:causes linked to the disease (eg, changes in disease pathology or progression) and 
causes linked to the drug’s ability  to treat the disease ( eg, an increase in the level of inflammation 
and/or an increase in drug clearance, lead ingto inadequate levels of drug to 
maintain activity ).

STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 19
Approved , Date: [ADDRESS_493674] [ZIP_CODE].2.3. Dose A djustment in Patients with Loss of Response to Ustekinumab
Pharmacokinetic (PK) analy sis from the IMUNIT Istudy  showed that participant s who lost 
response to q12w dosing had lower serum ustekinumab concentrations than those who did not lose 
response, suggesting that lower drug levels may be associated with LoR.2Similarly , participant s 
with LoR to q8w dosing were also observed to have lower serum levels of drug compared with 
q8w participant s who did not lose response. Median serum ustekinumab concent rations at Weeks 8 
and 16 of q8w maintenance were 1.63 µg/mL  and 1.19 µg/mL , respectivel y, for participant s who 
met the criteria for dose adjustment , and 2.21 µg/mL and 2.04 µg/mL, respectively , for participants 
who did not need dose adjustment.[ADDRESS_493675] lower levels of drug than those with 
sustained response and considering the PK characteristics and exposure -response (E-R)
relationship of ustekinumab, a potential strategy  to address LoR is a dose escalation to raise serum 
drug levels , either in the form of an increase in dose or ashorten ingof the interval of ustekinumab 
administ ration. In IMUNITI, use of dose escalation to address LoR was studied only  in the q12w 
group ; participant s with LoR to q8w dosing received blinded sham dose escalation of continued 
q8w maintenance. Upon dose escalation from q12w to q8w, 55% regain edtheir response and 42% 
achieved remission by  [CONTACT_10585]16. Regaining of response was accompanied by a 4-fold increase in 
serum drug levels .28Thus, the concept of dose escalation for LoR is establ ished for the q12 w dose
and was accordingl yincluded in the approved European posology ; however, for patients losing 
response to the q8w dose there is currently  no established or approved strategy  to address theLoR.
During induction and maintenance, ustekinumab concentration was inversel y related to 
concentrations of C-reactive protein (CRP ). At Week [ADDRESS_493676] doses after regaining 
response . Schnitzler et al23reported that more than 70% of patients who underwent infliximab dose 
optimization could return to their original treatment regimen during follow -up. Furthermore, as 
Crohn’s disease is characterized by [CONTACT_393383], permanentl y high doses might not be needed 
to sustain response once regained, rather increased doses of drug would be required only until the 
flare quiesces or subsides.
There is evidence demonstrating that a strategy  of re-induc tion can be as effective aslong-term 
dose increase or interval shortening . Srinivasan et al25compared re-induction with shortened 
dosing intervals in patients who had lost response to standard maintenance dosing with either 
infliximab or adalimumab and found no significant difference in the incid ence of treatment failure 
at 12months follow -up (24% vs 15%, p=0.27 ).Although there were few patients and the dosing 
regimens varied, Heron12reported on 11 patients with Crohn’s disease on SC 90mg q4w 
ustekinumab with either clinical or endoscopic LoR who were dose adjusted with either SC (n=3) 
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 20
Approved , Date: [ADDRESS_493677] 2020or IV re-induction (n=8). The IV re-induction dose used was 260 mg IV in 2patient s and 390 mg
IV in 6patients. Five of the 8 (62.5%) participants receiving IV re-induction were in clinical 
remission or endoscopic response at follow -up (2 month s and 7 months, respectively ).Additional 
evidence supporting the efficacy  of re-induction has been demonstrated in a small number of 
patients (n=3) who had been initially  treated with non-weight -based SC induction andhad not 
demonstrated an adequate cl inical response to ustekinumab .19
Pharmacokinetic modeling of ustekinumab shows that IV re-induction with the approved 
6mg/kg dose would achieve an approximately  10-fold higher peak concentration than would be 
achieved with even more frequent SC doses of 90 mg, such as q4w, the attained serum ustekinumab 
exposure being similar to the exposure following the initial induction. Based on the PK analy sis, 
re-induction would not result in a meaningfull y higher usteki numab exposure than with the initial 
induction dose ,since at the time of the re-induction serum concentrations would be at relativel y 
lowlevels (1.19 µg/mL to 1.63 µg/mL ). The C maxafter re -induction would be expected to be onl y 
marginally  higher than the Cmaxobserved in the UNIT I-1 and UNITI -2 induction studies 
(126.1µg/mL and 124.4 µg/mL , respectivel y). Thereafter, serum concentrations would likely 
return to levels typi[INVESTIGATOR_393360] 16weeks, since 
median serum concentrations of ustekinumab are undetectable 16weeks after infusion of the 
induction dose.
2.3. Benefit /Risk Assessment
The safety  profile of ustekinumab is well documented, based on information from clinical trials 
and postmarketing experience. As of 31December 2017, an estimated 11,[ADDRESS_493678] 
been exposed to ustekinumab in the clinical development program, including 2,742 patients with 
Crohn’s disease. The estimated cumulative exposure to ustekinumab from launch through 
31 December 2017 is 1,036,701 person- years across all disease indications.
The benefits of ustekinumab in patients with moderate to severe Crohn’s disease have been well 
characterized, with a significant improvement in control of disease and a potential for decreased 
colectom y, lower frequency  of hospi[INVESTIGATOR_059], and improved quality  of life.
Re-induction dosing for LoR employ sthe currently  approved initial IV induction dose that was
demonstrated to be safe and effective in clinical trials. T his incremental , short -term increase in 
serum levels of ustekinumab is unlikely  to have safet y consequences compared with the initial 
induction; indeed, no dose response was observed for safety between the different induction doses 
tested in clinical trials with ustekinumab. In Crohn’s disease induction studies, no events of 
anaph ylaxis or other serious infusion reactions were reported following the single IV dose; 2.4% 
of 466 participants who received placebo and 2.6% of 470 participants who received the 
recommended dose of ustekinumab reported adverse events occurring during or within an hour of 
the infusion.
As described in Section 2.2.3 , it is likely  that serum concentrations after re-administration of the 
IV induction dose in patients on q8w maintenance would be similar to those after the initial IV
induction dose administration. Use of the approved maintenance dose and dosing interval after IV 
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 21
Approved , Date: [ADDRESS_493679] recent of these reports
(Heron 201812), in which 8 patients with Crohn’s disease who were on SC 90 mg q4w
ustekinumab, with either clinical or endoscopic LoR, were dose adjusted with IV re -induction. Of 
the 8 patients who received IV re-induction , 5(62.5%) were in clinical remission or endoscopic 
response at follow -up.
In this study , the potential risks of treatment with ustekinumab (eg, serious infections, including 
tuberculosis [TB] and hypersensitivity  reactions) are addressed in multiple way s:
The inclusion/exclusion criteria set appropriate limits regarding, for example, infections or 
predisposition to infections, history  of reactions to biologic agents, and baseline laboratory 
abnormalities (see Sections 5.1and 5.2, respectively ).
Comprehensive medical monitoring of data by [CONTACT_393384], vital signs, physical 
examination, and laboratory  test results to evaluate individual cases as well as potential 
emerging safety  trends (see Schedule of Activities and Section 8.2).
Certain concomitant medications have been prohibited and limitations set on dose levels of 
permitted concomitant medications in this study , such as high dose glucocorticoids and use of 
multiple biologics simultaneously , which could introduce safet y risks due to over-suppression 
of the immune sy stem (see Section 6.5).
Finally , the steroid- sparing effects of ustekinumab are evaluated by [CONTACT_393385] 8 (see Section 6.5.2 ). This may benefit participants by 
[CONTACT_393386] -related complications ; however, if a 
participa nt experiences a worsening in their disease activity  while tapering corticosteroids, 
further dose decreases can be suspended, and/or the participant’s oral corticosteroid dose may 
be temporaril y increased if deemed necessary  by [CONTACT_093] .
The benefi t risk ratio is considered favorable, g iven the potential benefit of a re -induction strategy 
to regain response to ustekinumab with asingle intervention ,and considering the current 
understanding of the safety  profile of ustekinumab and the cumulative ong oing safet y evaluation s.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 22
Approved , Date: [ADDRESS_493680] [ZIP_CODE]. OBJECTIVE S ANDENDPOINTS
OBJECTIVES
Primary Objective
The primary  objective is to evaluate the achievement of clinical response at Week 16 following a 
single IV re -induction dose of 6mg/kg ustekinumab , compared with continuing regular SC q8w 
90mg ustekinumab administration, in participants with secondary  LoR to SC q8w 90mg 
ustekinumab maintenance therap y.
Secondary Objectives
The secondary  objectives are to:
Evaluate the achievement of clinical respo nse and clinical remission, as well as the reduction 
in inflammatory  biomarkers (serum CRP and fecal calprotectin [ fCal] levels), after IV 
ustekinumab re -induction.
Assess the overall safet y of IV ustekinumab re -induction.
Other Objectives
Other objectives areto assess endoscop y and patient -reported assessment of bowel inflammation
following IV ustekinumab re-induction, and to assess the steroid -sparing effect and 
pharmacokinetics following a single IV re -induction dose of 6 mg/kg ustekinumab.
ENDPOINTS
Primary Endpoint
The primary  endpoint is c linical response at Week 16, defined as a ≥100- point reduction from the 
baseline CDAI score or a CDAI  score <15 0points.
Secondary Endpoints
The major secondary  endpoints, listed in order of testing, are as specifie d below:
Clinica l remission at Week 16, defined as a CDAI score of <150 points.
Clinical response at Week 8, defined as a ≥100- point reduction from the baseline CDAI score 
or a CDAI score <150.
Clinical remission at Week 8, defined as a CDAI score of <150 points.
Normalization of CRP and/or fCal concentration(s) at Week 16,among participants with an 
elevated CRP and/or fCal at baseline .
Other secondary  endpoints are:
Clinical remission at Week 24, defined as a CDAI score of <150 po ints.
Clinical response at Week 24, defined as a ≥100- point reduction from the baseline CDAI score 
or a CDAI score <150.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 23
Approved , Date: [ADDRESS_493681] 2020Normalization of CRP and/or fCal concentration(s) at Week 24,among participants with an 
elevated CRP and/or fCal at baseline.
Safety  endpoints, including the proportion of participants with at least one adverse event and 
subcategories of adverse events (all infections, all serious adverse events and serious 
infections), as well as changes in clinical laboratory  test results.
Other Endpoints
The following other endpoints will be assessed:
Endoscopy
Reduction of ≥50% from baseline in simple endoscopic score for Crohn’s disease 
(SES- CD) at Week 16.
Reduction of ≥3points from baseline in SES- CD at Week 16.
SES-CD score ≤3 at Week 16.
Complete absence of mucosal ulcerations in any ileocolonic segment at Week 16
Change from baseline in simple endoscopic score for SES-CDscore at Week 16 .
Proportion of participants with a minimum of 25% improvement from baseline in 
SES-CD score at Week 16.
Patient- reported outcomes
Change from baseline in the sum of the number of stools and the abdominal pain scores 
in the prior 7 days, without weighting (PRO- 2), at Week 16.
Change from baseline in the weighted sum of the abdominal pain and stool frequency 
subscores of the CDAI (PRO -2 weighted) at Week 16.
Change from baseline in the Inflammatory  Bowel Disease Questionnaire (IBDQ) score 
(including IBDQ domains) at Week 16.
Proportion of participants with IBDQ remission (IBDQ score >170) at Week 16 .
Steroids
Proportion of participants with corticosteroid- free response at Week 24, defined as a 
CDAI  score decrease ≥100 from baseline .
Proportion of participants with corticosteroid- free response at Week 24, defined as a 
CDAI score decrease ≥100 from baseline, amon g participants who were on 
corticosteroids at baseline.
Proportion of participants with corticosteroid -free remission at Week 24, defined as a 
CDAI  score <150, among participants who were on corticosteroids at baseline .
Pharmacokinetics
Serum ustekinumab concentrations and PK parameters.
Proportion of participants with anti- ustekinumab antibodies.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 24
Approved , Date: [ADDRESS_493682] 2020Additionally , the following other combined endpoints will be assessed at Week 16:
Proportion of participants with clinical remission and ≥50% reduction from baseline in CRP 
or fCal.
Proportion of participants with clinical remission and ≥50% reduction from baseline in CRP 
or fCal, among participants with elevated CRP (>3mg/L) or elevated fCal (>250 mg/kg) at 
baseline .
Proportion of participants with clinical rem ission and CRP <3 mg/L and fCal ≤250 mg/kg .
Proportion of participants with clinical remission and CRP <3mg/L  and fCal ≤250 mg/kg, 
among participants with elevated CRP (>3 mg/L ) or elevated fCal (>250 mg/kg) at baseline .
Proportion of participants with clinical biomarker respo nse (clinical response and 
≥50% reduction from baseline in CRP or fCal ).
Proportion of participants with clinical biomarker respo nse (clinical response and 
≥50% reduction from baseline in CRP or fCal), among participants with elevated CRP 
(>3mg/L ) or elevated fCal (>250 mg/kg) at baseline .
Proportion of participants with clinical response and CRP <3 mg/L  and fCal ≤250 mg/kg .
Proportion of participants with clinical response and CRP <3mg/L  and fCal ≤250 mg/kg , 
among participants with elevated CRP (>3 mg/L ) or elevated fCal (>250 mg/kg) at baseline .
Refer to Section 8, Study Assessments and Procedures ,for evaluations related to endpoints.
HYPOTHESIS
The study  hypothesis is that in patients with secondary  LoR to SC q8w 90mg ustekinumab 
maintenance treatment, a single weight -tiered based IV ustekinumab re-induction dose of 
6mg/kg (ie,IVustekinumab/SC placebo at Week 0) followed by q8w 90mg ustekinumab 
maintenance will result in a higher clinical response rate (defined as a ≥100 -point reduction from 
the baseline CDAI score, or a CDAI score <150) compared with continuous SC q8w 90mg 
ustekinumab maintena nce treatment (ie,IVplacebo/SC ustekinumab at Week 0) after 16 weeks.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 25
Approved , Date: [ADDRESS_493683] [ZIP_CODE]. STUDY DESIGN
4.1. Over allDesign
This is a randomized, double -blind, placebo -controlled, multicenter, 24-week , Phase 3b study  in 
adult patients with moderate lyto severe lyactive Crohn’s disease who initially  responded to 
ustekinumab induction therap y per label followed, at any time, by [CONTACT_393387] q8w 
ustekinumab maintenance therap y. The benefit of a single weight -tiered based IV re-induction 
dose of 6mg/kg body  weight ustekinumab versus continuous SC q8w maintenance treatment will 
be evaluated.
Initial response criteria are described in Section 10.2, Appendix 2.
Secondary  LoR is defined as aCDAI score of 220 and ≤[ADDRESS_493684] one of thefollowing:
Elevated CRP (>3.0 mg/L ); and/or
Elevated fCal (>250 mg/kg); and/or
Endoscopy  (ileocolonoscopy ) performed ≤3months before baseline with evidence of active 
Crohn’s disease (defined as one or more ulcerations in the ileum and/or colon).
The study  will include approximately  200 participants. Eligible participants will be randomly 
assigned to one of thefollowing 2intervention group s,in a 1:1 ratio, using permuted block 
randomization stratified at the study  level by [CONTACT_3445]’s baseline CDAI score (≤300 or >300) 
and prior biologic failure (y es or no) at baseline.
Ustekinumab re -induction: IV ustekinumab and SC placebo at Week 0.
Continuous maintenance: IV placebo and SC ustekinumab at Week 0.
At baseline (Week 0),approximately  8weeks (±2weeks) after the previous per label dose of SC
90mg ustekinumab maintenance, participants will undergo clinical assessments. Following 
randomization, participants will receive IV ustekinumab 6mg/kg and SC placebo or IV placebo 
and SC ustekinumab [ADDRESS_493685]-of- care practices at the study  site; there 
must be no concurrent administration of I V and SC study  intervention (see Section 6.1).
At Week8 and Week 16, all participants will receive SC ustekinumab [ADDRESS_493686] study  intervention administration 
(ie,Week 36 for participants who complete the final study  intervention visit at Week 16); this may 
be conducted at a site visit or by  [CONTACT_756].
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 26
Approved , Date: [ADDRESS_493687] 2020Key efficacy  assessments willinclude clinica l response (CDAI reduction ≥100), clinical remission 
(CDAI value < 150) and biomarker normalization. Safety asses sments will include the monitoring 
of adverse events , vital signs, and clinical laboratory  tests.
A diagram of the study  design is provided in Section 1.2, Schema . The timing of study 
interventions and clinical assessments is summarized in Section 1.3, Schedu le of Activities.
4.2. Scientific Rationale for Study  Design
Study Population
The population for this study  includes only adult patients with moderate lyto severe ly active
Crohn’s disease who experience a secondary  LoR to SC q8w ustekinumab maintenance treatment , 
represent ative of the population of patients with Crohn’s disease in which ustekinumab is 
approved . Since anti-TNF agents are often the first -line biologics used in the treatment of patients 
with Crohn’s disease, based on recommended treatment algorithms11,17, and the relativel y recent 
approval of ustekinumab for the treatment of Crohn’s disease, these patients likely  have few 
remaining therapeutic options ; hence regain ingand preserv ing the response to ustekinumab is 
essential for the long-term management of their diseas e. While the current EU label ingfor 
ustekinumab provides the option for dose adjustment in patients with LoR to q12w maintenance, 
there is no option for patients with LoR to q8w maintenance. Since dose adjustment using IV 
re-induction has not yet been studied in a controlled manner in these patients, this represents an 
important gap in the scientific literature that isimportant for evidence- based practice. This study 
will fill this gap by [CONTACT_1541] a prospective, randomized direct comparison of IV re-induction with
continuous q8w maintenance therap y.
To mimic normal clinical practice and consistent with other studies , enrolled participants will be 
permitted to receive concomitant immunosuppressants or oral corticosteroids for the treatment of 
Crohn’s disease during the study ,provided the y were on a stable dose for a specified period prior 
to baseline and will maintain a stable dose throughout the trial, with the exception of oral 
corticosteroids which will be tapered in W eek8CDAI -70responders.
Blinding, Control
This study  is double -blind and utilizes a double -dummy  design to maintain blinding and prevent 
bias. Placebo is included in each intervention group for blinding purposes, rather than for 
determination of the effect of the study  intervention (IV re-induction with ustekinumab versus 
continuous SC ustekinumab maintenance therapy ). All participants will receive ustekinumab 
treatment until Week 24,at which time they  will receive standard -of-care therap y.
Dosing, Study Duration
The dosage and dosing interval are designed to align with the currently  approved label for 
ustekinumab for Crohn’s disease in both the EU and the US .
The relativel y short duration of the study  (24 weeks, with a safet y follow up at Week 36) is
intended to provide evidence for the effectiveness of re-induction without requiring prolonged 
treatment ,should a patient not respond to the therapeutic intervention. Based on PK modeling, it 
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 27
Approved , Date: [ADDRESS_493688] ion or dose escalation after 16 weeks of therap y. The primary  endpoint of 
clinical response is designed to mimic the real-world treatment of patients with Crohn’s disease.
The population of patients enrolled in this trial (ie,with LoR despi[INVESTIGATOR_393361] a likely  history  of previous, inadequate response to biologic agents) is 
expected to be difficult to treat. In this refractory  setting the primary  goal is to achieve a clinical 
response, rather than clinical remission or endoscopic response. In addition, it is not clear if
patients who experience LoR necessaril y have associated endoscopic recurrence, nor has it been 
established for any biologic that endoscopic response can be regained with dose adjustment for 
LoR in patients with Crohn’s disease . The use of the CDAI  to assess response to treatment has 
been demonstrated in clinical trials for recentl y approved therapeutics for Crohn’s diseas e.9,21
This study  will also evaluate patient -reported outcomes (PROs), recognizing theimportant 
information these tools can provide to help clinicians evaluate response to therapi[INVESTIGATOR_014]. The 
evaluation of endoscopic outcome measures at Week 16will seek to provide additional 
information onthe efficacy of IV re -induction and of mucosal inflamm ation in the setting of LoR . 
Additional evaluations will examine the pharmacodynamics of IV re-induction, correlating the PK 
with clinical outcomes (eg, CDAI, changes in CRP and fCal , and endoscopic measures where 
applicable ); these evaluations may provide further information to enable clinicians tomake 
informed treatment decisions for patients with a secondary  LoR to ustekinumab.
Database Locks
Two database locks are planned for this study . The first (the primary  endpoint database lock) will 
occur when all participants have completed Week [ADDRESS_493689] terminated study  participation prior 
to Week 16. The second (the final database lock) will occur when all participants have completed 
Week [ADDRESS_493690] terminated study  participation prior to Week 36.
At the time of the Week 16 database lock, the sponsor (except for site monitors, who have 
interactions with the investigative sites) will become unblinded to treatment assignment. The study  
blind will be maintained for investigators, site personnel, participants, andsponsor site monitors 
until the final assessments have been completed for all study  participants at Week 36. This measure 
will mitigate the potential bias in the remaining investigator and participant assessments.
4.2.1. Study -Specific Ethical Design Considerati ons
Potential participants will be fully informed of the risks and requirements of the study . During the 
study , participants will be given any new information that may affect their decision to continue 
participation. They  will be told that their consent to participate in the study  is voluntary  and may  be 
withdrawn at any time with no reason given and without penalt y or loss of benefits to which they 
would otherwise be entitled. Only participants who are fully able to understand the risks, benefits, 
and potential adverse events of the study , and who provide their consent voluntarily  will be enrolled.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 28
Approved , Date: [ADDRESS_493691] 2020The efficacy  and safety profile for ustekinumab inthe treatment of moderately  to severel y active 
Crohn’s disease iswell-established . All participants will receive active treatment for their disease 
throughout the stud y, including those patients who receive IV placebo. Additionall y, the dosage and 
dosing interval used in this study  are designed to align with the currently  approved label for 
ustekinumab for Crohn’s disease in both the EU and the US .
The total blood volume to be collected in this study  (see Section 8) is considered an acceptable 
amount for the study  duration and study  population based upon the standard of the World Health 
Organi zation (450 mL once every  2months, up to a maximum of 3 L over 12 consecutive months 
for blood donation).
4.3. Justification for Dose
The IV ustekinumab re-induction dose (6mg/kg) is the approved dose for the initial induction 
with ustekinumab in patients with Crohn’s disease, which is being investigated in this study  for 
re-induction in patients with secondary  LoR to ustekinumab.
The maintenance dose of ustekinum ab (90mg) SC q8w is the approved dose for maintenance 
treatment in patients with Crohn’s disease in the US and for EU patients who have not responded 
adequatel y to ustekinumab induction treatment or q12w treatment. All participants must have 
demonstrated secondary  LoR to current SC q8w ustekinumab maintenance therap y to qualify for
this study (see Section 4.1); any  patients who initially  did not respond adequately  toustekinumab 
q12w treatment must also have not responded to q8w treatment before being considered eligible 
for this study .
The rationale for re-induction rather than dose interval shortening to address LoR in patients on 
q8w maintenance is supported by  2key arguments:
Ustekinumab PK analy sis shows that ustekinumab clearance is increased with increased levels 
of underl ying inflammation, as measured by [CONTACT_319125]. This raises the possibility that ustekinumab 
clearance could slow as inflammation is suppressed and response is regained and, i f so, th at a 
longer -term increase in dose might not be necessary  to sustain adequate ustekinumab levels 
once response has been regained.
Crohn’s disease is characterized by [CONTACT_393383], which suggests that increased doses of 
drug would be required only until the flare is quiesced or has subsided, after which 
maintenance dosing can be continued.
The therapeut ic intervention takes advantage of an approved induction dose and route of 
administration with known PK characteristics and safet y, minimizing risk to the study  participants, 
particularl y over an extended time since no safety  data exist for long-term use of 90-mg SC q6w 
or q4w dosing .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 29
Approved , Date: [ADDRESS_493692] completed the study  if he /she has completed assessments 
through the 24-week treatment period and the Week 36safet yfollow up. Participants will be 
considered to have completed the primary  efficacy  period of the study  if they  have completed the 
study  assessments through Week 16(or at an earl y termination visit).
The end of study  is considered the last scheduled study  assessment for the last participant in the 
study . The final data from the study  site will be sent to the sponsor (or designee) after completion 
of the final participant assessment at that study  site, in the time frame specified in the Clinical Trial 
Agreement.
5. STUDY POPULA TION
Screening for eligible participants will be performed within 5weeks before the first administration 
of study  intervention at Week 0.Refer to Section 5.4for information on repeat of any screening 
procedures .
The inclusion and exclusion criteria for enrolling participants in this study  are described below . If 
there is a question about any of thesecriteria, the investigator must consult with the appropriate 
sponsor representative and resolve any  issues before enrolling a participant in the study . Waivers 
are not allowed. For a discussion of the statistical considerations of participant selection, refer to 
Section 9.2.
5.1. Inclusion Criteria
Each potential participant must satisfy  all the following criteria to be enrolled in the study :
1. Male or female aged 18years (or the legal age of consent in the jurisdiction in which 
the study  is taking place if older than 18 years).
2. A history  of Crohn’s disease or fistulizing Crohn’s disea se of at least 3 months’ duration, 
with colitis, ileitis, or ileocolitis, confirmed at any time in the past by [CONTACT_237450] y, 
histology , and/or endoscopy .
3. Criterion changed per Amendment 4.
3.1 I nitiall y responded to ustekinumab induction therapya, administered according to the local 
label, followed b y secondary  LoR to ustekinumabb.
aInitial response to ustekinumab as defined in Section 10.2, Appendix 2.
bSecondary LoR to ustekinumab is defined as active disease at study baseline ,proven 
by a CDAI score of 220 and ≤[ADDRESS_493693] one of the following:
Elevated CRP (>3.0 mg/L) ; and/or
Elevated fCal (>250 mg/kg );and/o r
Endoscopy (performed ≤3months before baseline ) with evidence of active 
Crohn’s disease ( defined as one or more ulcerations in the ileum and/or colon) .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 30
Approved , Date: [ADDRESS_493694] 2 doses of SC 90 mg ustekinumab treatment 8 weeks 
apart prior to enrollment.
4. The following medications for the treatment of Crohn’s disease are permitted providing 
thedoses indicated are stable for at least 3weeks before baseline or have been 
discontinued at least 3 weeks before baseline :
Oral 5-aminosalicy lic acid (5-ASA )compounds.
Oral corticosteroids (eg, prednisone, budesonide) at a prednisone -equivalent dose of 
≤40mg/day  or ≤9mg/day of budesonide.
Antibiotics used as theprimary  treatment of Crohn’s disease .
Any participants receiving conventional immunomodulators (ie, azathioprine [AZA ], 
6-mercaptopurine [6-MP], or methotrexate [ MTX ]) must have been taking them for 
≥12weeks and must have been on a stable dose for a least [ADDRESS_493695] results are within the specified limits at screening:
Hemoglobin  8.5 g/dL (85 g/L) .
White blood cell (WBC) count 3.5 x 103/L (3.5 GI /L).
Neutrophils 1.5 x 103/L (1.5 GI/L) .
Platelets 100 x 103/L (100 GI /L).
Serum creatinine <1.7 mg/dL (≤150µmol/L ).
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline 
phosphatase levels ≤[ADDRESS_493696] .
Direct (conjugated) bilirubin < 1.0mg/dL (<0.01 g/L).
NOTE: A repeat of these screening laboratory  tests is allowed during the screening phase . 
The investigator may consider the participant eligible if the previously  abnormal 
laboratory  test result is within the acceptable range on repeat testing in the laboratory.
6. Criterion changed per Amendment 1.
6.1 Meet the following TB screening criteria:
Nohistory  of latent oractive TB before screening. An exception is made for 
participants who have a history  of latent TB and are currentl y receiving treatment for 
latent TB, will initiate treatment for latent TB prior to first administration of study  
intervention, or have documentation of having completed appropriate treatment for 
latent TB within 5years prior to the first administration of study  intervention . It is 
the responsibility  of the investigator to verif y the adequacy  of previous TB treatment 
and provide appropriate documentation.
No signs or s ymptoms suggestive of active TB upon medical history and/or physical 
examination.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 31
Approved , Date: [ADDRESS_493697] 2020No recent close contact [CONTACT_4490] a person with active TB . If there has been such contact,
the participant will be referred to a physician specializing in TB to undergo additional 
evalua tion and, if warranted, will receive appropriate treatment for latent TB prior to
or simultaneously  with the first administration of study  intervention .
Within 5weeks before the first administration of study  intervention , hasa negative 
QuantiFERON®-TB test result ,or a newl y identified positive QuantiFERON -TB test 
in which active TB has been ruled out and for which appropriate treatment for latent 
TB has been initiated prior tothe first administration of study  intervention . If the 
QuantiFERON -TB test is not approved or is not registered in a country or if the 
tuberculin skin test is mandated by [CONTACT_72952], a negative tuberculin skin 
test (see Section 10.3 , Appendix 3),or a newl y identified positive tuberculin skin test 
in which active TB has been ruled out and for which appropriate treatment for latent 
TB has been initiated prior to the first administration of study  intervention, is 
additionally  required within 5weeks prior to the first administration of study  
intervention .
Participants who have an indeterminate result should have the test repeated. 
Participants with persistently  indeterminate QuantiFERON -TB test results may be 
enrolled without treatment for latent TB if active TB is ruled out, their chest 
radiograph shows no abnormality  suggestive of TB (active or old, inactive TB), and 
the participant has no additional risk factors for TB as determined by [CONTACT_093]. 
This determination must be promptly  reported to the sponsor’s medical monitor ,
recorded in the participant's source documents ,and initialed by [CONTACT_093].
NOTE: The QuantiFERON -TB test and/orthe tuberculin skin test is/are not required 
to be performed at screening for participants with a history of latent TB and ongoing 
treatment for latent TB or documentation of having completed adequate treatment as 
described above . Participants with documentation of having completed adeq uate 
treatment as described above are not required to initiate additional treatment for latent 
TB.
Has achest radiograph (at least a posterior -anterior view) or computed tomograph y 
of the chest , taken within 6months before the first administration of study 
intervention and read by a qualified radiologist, with no evidence of current ,active 
TB or old ,inactive TB.
7. A female participant must be:
Not of childbearing potential (as defined in Section 10.8, Appendix 8)
OR
If heterosexually  active, must be practicing a highly  effective method of birth control ,
consistent with local regulations regarding the acceptable methods of contraception 
for those participating in clinical studies ,for the duration of their participation in the 
study  and for 15weeks after the last dose of study  intervention , the end of relevant 
systemic exposure .
NOTE: If the particip ant’s childbearing potential changes after the start of the study , 
that participant must begin practicing a highl y effective method of birth control as 
described above.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 32
Approved , Date: [ADDRESS_493698] 2020OR
Not be heterosexually  active and agrees to utilize a highly  effective method of birt h 
control if they  become heterosexually  active during their participation in the study .
Examples of highly  effective methods of contraception are presented in Section 10.[ADDRESS_493699] a negative highl y sensitive 
serum (-human chorionic gonadotropin [-hCG ]) pregnancy  test at screening and a 
negative urine pregnancy  test at baseline and prior to each administration of study  
intervention .
9. A male participant who isheterosexually  active with a woman of childbearing potential 
and is not surgicall y sterile must agree to use a double -barrier method of birth control and 
not donate sperm during the study  and for 15weeks after receiving study  intervention .
10. W illing and able to adhere to the prohibitions and restrictions specified in this protocol.
11. Sign an informed consent docume nt indicating that he/she understands the purpose of and 
procedures required for the study  and iswilling to participate in the stud y.
5.2. Exclusion Criteria
Any potential participant who meets any of the following criteria will be excluded f rom 
participating in the study:
1. C omplications of Crohn’s disease ,such as symptomatic strictures or stenoses, short gut 
syndrome, or any other manifestation that might be anticipated to require surgery , could 
preclude the use of the CDAI to assess response to therapy , or would possibly  confound 
the ability  to assess the effect of treatment with ustekinumab.
2. Currently  has or issuspected to have an abscess. Recent cutaneous and perianal abscesses 
are not exclusionary if drained and adequatel y treated at least 3 weeks before baseline (or 
8weeks before baseline for intra-abdominal abscesses )provided there is no anticipated
need for any further surgery . Participant s with active fistulas may  be included if there is 
no anticipation of a need for surgery  and there are curr ently no abscesses identified.
3. A ny kind of bowel resection within 6months or any other intra-abdominal surgery  within 
3months before baseline.
4. A draining (ie, functioning) stoma or ostomy .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 33
Approved , Date: [ADDRESS_493700] [ZIP_CODE]. Criterion changed per Amendment 4:
5.1 R eceived any of the following prescribed medications or therapi[INVESTIGATOR_393362]:
Use of IV ustekinumab re-induction after the initial weight -tiered -based IV induction 
dose of ustekinumab.
Any known history  of shortened frequency  of SC dose administrat ion (<q8w) for a 
secondary  loss of response where the participant did not, in the opi[INVESTIGATOR_33398], benefit from the dose interval shortening.
Intravenous corticosteroids as a treatment for Crohn’s disease within 3 weeks before 
baseline.
Oral immunomodulatory agents other than AZA, 6-MP, or MTX (eg, Janus kinase 
[JAK] inhibitors, 6-thioguanine [6-TG], cyclosporine, tacrolimus, sirolimus, 
tofacitinib, or my cophenolate mofetil) within 4 weeks before baseline.
NOTE: See Inclusion Criterion 4 for restrictions on typi[INVESTIGATOR_393363] ( AZA, 6 -MP or MTX ).
Any other investigational agent for Crohn’s disease (eg other biologics, small 
molecules or anti -sense RNA such as mongersen ), unless at least 3 months or 5half-
lives (whichever is lo nger) have elapsed since the last dose.
Treatment with apheresis (eg, Adacolumn apheresis) or total parenteral nutrition as 
a treatment for Crohn’s disease within [ADDRESS_493701] 4 months that is positive for an enteric 
pathogen, including Clostridium difficile toxin, unless a repeat examination is negative 
and there are no signs of ongoing infection with that pathogen.
7. R eceived a Bacille Calmette -Guérin (BCG) vaccination within 12months beforebaseline 
or an y other live bacterial or live viral vaccination within [ADDRESS_493702] infection 
(eg,recurrent pyelonephritis or chronic nonremitting cystitis), or open, draining, or 
infected skin wounds or ulcers.
9. A ny current signs or symptoms of infection. Established non -serious infections (eg,acute 
upper respi[INVESTIGATOR_2826], simple urinary  tract infection) need not be considered 
exclusionary  at the discretion of the investigator.
10. A history  of serious infection (eg,sepsis, pneumonia, or pyelonephritis), including any 
infection requiring hospi[INVESTIGATOR_26109] I V antibiotics, for 8 weeks before baseline.
11. Evidence of a herpes zoster infection 8 weeks beforebaseline.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 34
Approved , Date: [ADDRESS_493703] 202012. A history  of latent or active granulomatous infection, including histoplasmosis or 
coccidioidomy cosis, before screening ; refer to Inclusion Criteri on [ADDRESS_493704] radiograph, unless definitively  
resolved surgically  or by [CONTACT_393388].
14. A current or (lifetime )history  ofa nontuberculous mycobacterial infection or serious 
opportunistic infection (eg, Cytomegalovirus colitis, Pneumocy stis carinii, aspergillosis).
15. K nown to be infected with human immunodeficiency  virus , hepatitis B, or hepatitis C.
16. S evere, progressive, or uncontrolled renal, hepatic, hematological, endocrine, pulmonary , 
cardiac, neurologic, cerebral, or ps ychiatric disease, or any signs orsymptoms thereof.
17. A transplanted organ , with theexception of a corneal transplant performed >12weeks 
before screening .
18. A known history  of lymphoproliferative disease, including lymphoma, or signs and 
symptoms suggestive of possible ly mphoproliferative disease, such as ly mphadenopathy 
and/or splenomegal y.
19. A ny known malignancy or a history  of malignancy , with the exception of:basal cell 
carcinoma; squamous cell carcinoma in situ of the skin; cervical carcinoma in situ that 
has been treated with no evidence of recurrence; or squamous cell carcinoma of the skin 
that wa streated with no evidence of recurrence wi thin [ADDRESS_493705] had a substance abuse (drug or alcohol) problem within the 12months 
before baseline.
23. K nown allergies, hypersensitivity , or intolerance to ustekinumab or its excipi[INVESTIGATOR_840] (refer 
to the Investigator's Brochure for further details).
24. C urrently  is participat ing in or is intending to participate in any other study  using an 
investigational agent or procedure during participation in this study .
25. A woman who is pregnant, or breast feeding , or planning to becom e pregnant ,or is a man 
who plans to father a child while enrolled in this study  or within 15weeks after the last 
dose of study  intervention .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 35
Approved , Date: [ADDRESS_493706] of the participant (eg, compromise the well-being) or that could 
prevent, limit, or confound the protocol -specified assessments.
27. Criterion added per Amendment 3:
During the 6weeks prior to baseline, have had ANY of (a) confirmed SARS -CoV -2 
(COV ID-19) infection (test positive), OR (b) suspected SARS -CoV -2 infection (clinical 
features without documented test results), OR (c) close contact [CONTACT_4490] a person with known 
or suspected SARS -CoV -2 infection.
Exception: may be included with a documented negative result for a validated 
SARS -CoV -[ADDRESS_493707]
obtained at least 2weeks after conditions (a), (b), or (c) above (timed from 
resolution of key  clinical features if present, eg, fever, cough, d yspnea)
AND
with absence of ALL  conditions (a), (b) and (c) above during the period between 
the negative test result and the baseline stud y visit.
Notes on COVID -19-related Exclusion :
 If a patient is excluded due to recent COVID -19-related features, the reason for 
screen failure should be documented in the case report form (CRF) under the 
exclusion criterion of having a condition for which study  participation would not 
be in the patient ’s interest or could confound study  assessments.
 The field of COVI D-related testing (for presence of, and immunity  to, the 
SARS -CoV -2 virus) is rapi[INVESTIGATOR_393364]. Additional testing may be performed as 
part of screening and/or during the study  if deemed necessary  by [CONTACT_393389], guidance from authorities, or standards 
of care.
Precautions:
For those patients who may carry a higher risk for severe COVID -19 illness (eg, patients 
aged over 65years), follow the guidance from local health authorities when considering 
the potential benefits and risks of enrolling patients into the study  and during study 
participation.
NOTE: Investigators should ensure that all study enrollment criteria have been met at screening. 
If a participan t's clinical status changes (including any available laboratory  results or receipt of 
additional medical records) after screening but before the first dose of study  intervention is given 
such that he/she no longer meets all eligibility  criteria, then the participant should be excluded 
from participation in the study . The required source documentation to support meeting the 
enrollment criteria are indicated in Section 10.6 , Appendix 6.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 36
Approved , Date: [ADDRESS_493708] ylerestrictions 
during the study  to be eligible for participation:
1. Agree to follow all requirements that must be met during the study  as noted in the 
Inclusion and Exclusion Criteria (eg, contraceptive requirements).
2. M ust not receive ustekinumab outside of the study or participate in any other clinical 
study  with an i nvestigat ional agent while in this study . If aparticipant intend sto receive 
ustekinumab or participate in any  other clinical study  with an investigational agent, they 
must terminate s tudy participation and an earl y termination visit should occur.
3. Must agree to adhere to the restrictions/prohibitions regarding concomitant therapi[INVESTIGATOR_393365] y (see Section 6.5).
4. Must agree not to receive a live virus or live bacterial vaccination, including a BCG 
vaccination, during the study  or for [ADDRESS_493709] for completeness.
The participant identification and enrollment log will be treated as confidential and will be filed 
by [CONTACT_23854]. To ensure participant confidentiality , no copy will be made. 
All reports and communications relating to the study  will identify  participants by [CONTACT_90802] (as allowed b y local regulations) . In cases where 
the participant is not randomized into the study , the date seen and age at initial informed consent
(as allowed b y local regulations) will be used.
If a participant does not meet all inclusion and exclusion criteria as listed inSections 5.1and 5.2
(ie,is a screen failure), but at some point is expected to meet the study eligibility  criteria, the 
participant may  be rescreened. Participants who are rescreened will be assigned a new part icipant 
number, undergo the informed consent process, and then restart a new screening phase.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 37
Approved , Date: [ADDRESS_493710] [ZIP_CODE]. STUDY INTERVENTION
6.1. Study Interventions Administered
Study  intervention will start at baseline (Week 0), approximately  8weeks (±2weeks) after the 
previous dose of per label SC 90mg ustekinumab maintenance treatment . The date ofthe previous 
dose of ustekinumab will be recorded in the case report form (CRF) .
To maintain the double -blind , at Week 0 all participants will receive one IV infusion of 
ustekinumab 6mg/kg or placebo plus oneSC injection of ustekinumab [ADDRESS_493711] be no concurrent administrat ion of study  intervention 
(ie, IV and SC ).The minimum required time windows between administration of IV infusion and 
SC injection at Week 0are indicated below and in Figure 2:
If the SC injection is administered first, the IV infusion must not begin until at least 30minutes 
after completion of the SC injection.
If the IV infusion is administered first, the SC injection must not begin until at least 
120minutes after the start of the IV infusion, or at least 60minutes after completion of the 
IVinfusion.
The blood sample for trough serum PK must be collected at all study visits prior to the 
administration of ANY study  intervention (ie, IV or SC) as well as prior to the administration of 
standard -of-care therap y at Week 24.The post -IV infusion PK blood sample at Week 0 should be 
drawn approximately  60minutes after completion of the IV infusion.
Figure 2: Minim um Required Time Windows Between Administration of Study Intervention (IV or SC) 
at Week 0

STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 38
Approved , Date: [ADDRESS_493712] -
of-care therapy  with either ustekinumab maintenance therapy  per label or another treatment 
modality  at the discretion of their ph ysician.
For IV administration, the study  intervention will be administered to each participant as an infusion 
over a period of not less than 1hour by [CONTACT_3436]. The infusion should be completed within 
8hours of preparation. Details of each infusion will be recorded in the CRF (including date, start 
and stop times of the IV infusion, and volume infused).
Subcutaneous injections at Week [ADDRESS_493713] received the required training to perform self-
administration of SC injections. Details of each administration will be recorded in the CRF 
(including date and time of administration).
Study -site personnel will instruct participants on how to store study  intervention for at-home use
during Weeks 8 and 16. For each administration of study  intervention , the time and date of 
injection, whether study  intervention was self -administered, and if so, whether SC administration 
was complete (ba sed on the returned sy ringe [s])will be recorded in the CRF.
Detailed instructions on the administration of study  interventions are provided in the site 
investigational product procedures m anual.
Ustekinumab will be manufactured and provided under the responsibility  of the sponsor. Refer to 
the Investigator's Brochure for a list of excipi[INVESTIGATOR_840].
6.2. Preparation/Handling/Storage/A ccountability
6.2.1. Storage and Preparation
All study  intervention must be stored at controlled temperatures ranging from 2°C to 8°C, must 
notbe frozen, and must be protected from light. The solution in the vial or prefilled s yringe (PFS)
should not be shaken. Prior to administration, the solution should be visually  inspected for 
particulate matter and discoloration , and should not be used if it is discolored, cloudy , or if foreign 
particulate matter is present.
Study  intervention should be dispensed under the supervision of the investigator ,a qualified 
member of the stud y-site personnel, or by a hospi[INVESTIGATOR_307]/clinic pharmacist. Study  intervention in glass 
vials and PFS will be ready to use. The required volume of study  intervention will be prepared 
using the appropriate vials or PFS. Aseptic procedures must be used during the preparation and 
administration of the ustekinumab solution for I V infusion .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 39
Approved , Date: [ADDRESS_493714] 2020Refer to the pharmacy  manual/study  site investigational product and procedures manual for 
additional guidance on study  intervention preparation, handling, and storage .
6.2.2. Drug A ccountability
The investigator is responsible for ensuring that all study  intervention received at the site is 
inventoried and accounted for. The study  intervention administered to the participant must be 
documented on the intervention accountability  form. All study  intervention will be stored and 
disposed of according to the sponsor's instructions. Study -site personnel must not combine 
contents of the study  intervention containers.
Study  intervention must be handled in strict accordance with the p rotocol and container l abel and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Any study participant who will be self-administering study  intervention
at home during Week 8and Week [ADDRESS_493715] SCadministrations with time and date 
information in the participant’s d iary. Unused study  intervention must be available for verification 
by [CONTACT_456]'s study  site monitor during on-site monitoring visits. The return to the sponsor of 
unused study  intervention, or used returned study  intervention for destruction, will be documented 
on the intervention return form. When the study  site is an authorized destruction unit and study 
intervention supplies are destroy ed on -site, this must also be documented on the intervention return 
form.
Potentially  hazardous materials ,such as used ampules, needles, syringes and vials containing 
hazardous liquids, should be disposed of immediately  in a safe manner and therefore will not be 
retained for intervention accountability  purposes.
Study  intervention should be dispensed under the supervision of the investigator or a qualified 
member of the study -site personn el, or by  a ho spi[INVESTIGATOR_307]/clinic pharmacist. Study  intervention will be 
supplied only  to participants participating in the study. Study intervention may not be relabeled or 
reassigned for use by [CONTACT_48780]. The investigator agrees neither to dispense the study 
intervention from, nor store it at, any site other than the study sites agreed upon with the sponsor.
6.3. Measures to Minimize Bias: Randomization and Blinding
Intervention Allocation
Following clinical assessments at baseline, all enrolled participant s will be randomized in a 1:1 
ratio to 1of 2intervention group sto receive either IV ustekinumab 6mg/kg and SC placebo or 
IV placebo and SC ustekinumab 90 mg in a blinded manner.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 40
Approved , Date: [ADDRESS_493716] 2020Procedures for Randomization and Stratification
Central randomization will be implemented in this study . Participants will be randomly  assigned 
to 1 ofthe 2 intervention group sbased on a computer -generated randomization schedule prepared 
before the study  by [CONTACT_43754] . Permuted block randomization with 
stratification variables ,including the participant’s baseline CDAI score (≤300 or >300) and 
whether the participant had failed a prior biologic at baseline (yes or no), will be used. The
interactive web response system (IWRS) will assign a unique intervention code, which will dictate 
the intervention assignment and matching study  intervention kit for the participant. The requestor 
must use his or her own user identification and personal identification number when contact[CONTACT_393390] ,together with the relevant unique participant details to identify  the participant.
Blinding
At Week 0 participant s will receive a single IV infusion of study  intervention (ustekinumab 
6mg/kg or placebo) plus a single SC injection of study  intervention (ustekinumab 90mg or 
placebo) in a double -blind , double -dummy manner. During study  visits at Week8 and Week 16, 
all participant s will receive SC maintenance injections of [ADDRESS_493717] access to the IWRSto 
break the blind for an individual participant, if needed.
Data that may potentially  unblind the intervention assignment (ie, treatment allocation, study  
intervention preparation/accountability , and administration of study  intervention; see details in 
Section s6.1, 6.2and 6.3) will be handled with special care to ensure that the integrity of the blind 
is maintained and the potential for bias is minimized. This can include making special provisions, 
such as segregating the data in question from view by [CONTACT_473] , clinical team, or others as 
appropriate until the time of database lock and unblinding (at Weeks 16 and 36, see Section 4.2).
Under normal circumsta nces, the blind should not be broken until the database is finalized. The 
investigator may in an emergency  determine the identity  of the intervention by [CONTACT_117191]. While the responsibility  to break the intervention code in emergency  situations resides 
solely  with the investigator, it is recommended that the investigator contact [CONTACT_393391], before breaking the blind. Telephone contact [CONTACT_393392] w ill be available [ADDRESS_493718] be retained with the participant's source 
documents in a secure manner.
Participants who have had their intervention assignment unblinded should continue to return for 
scheduled evaluations .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 41
Approved , Date: [ADDRESS_493719] be recorded.
Each administration of study  intervention performed will be recorded in the participant’s source 
documents or diary . Study  intervention at Week [ADDRESS_493720] 
the corresponding date and time of the administration in the diary. Study site personnel will utilize 
participant’s diaries to ensure compliance and record at-home study  intervention administrations 
in the eCRF. Additionally , a sharps container to dispose of used syringes will be provided to 
participants who will administer any  study  intervention outside of the study  site. Participants will 
be instructed to return the sharps container , the syringe cartons and diaries to the study site at their 
next visit.
Additional details will be provided in the pharmacy  manual/stud y site investigational product 
manual provided separately .
6.5. Concomitant Therapy
Concomitant medication swill be reviewed at each visit. All concomitant therapi[INVESTIGATOR_014] (including 
vaccines) must be recorded throughout the study , from signing of the informed consent form (ICF)
to the last study  visit. Recorded information will include a description of the type of the therap y, 
treatment period, dosing r egimen, route of administration, and its indication.
6.5.1. Crohn’s Disease -specific Concomitant Medications
During the study , participants are permitted to receive oral 5-ASA compounds, the 
immunomodulators AZA, 6-MPand MTX, oral corticosteroids, and/or antibiotics for the treatment 
of Crohn’s disease ,provided the participant was on a stable dose for a specified period before
baseline (as defin ed in the inclusion criteria , Section 5.1). Participant s receiving these medications 
at baseline should maintain a stable dose throughout the study , except fororal corticosteroids 
which must be tapered in participants with a CDAI -70response at Week 8(see Section 6.5.2 ).
Enrolled participants should not initiate any of the following concomitant Crohn’s disease -specific 
medical therapi[INVESTIGATOR_393366] e study :
Oral or rectal 5- ASA compounds.
Immunomodulators (AZA, 6 -MP, or MTX).
Oral, parenteral, or rectal corticosteroids.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 43
Approved , Date: [ADDRESS_493721] 2020Immunomodulatory  biologic agents (including but not limited to TNF antagonists, 
vedolizumab, natalizumab, abatacept).
Experimental or investigational Crohn’s disease medications (including but not limit ed to 
thalidomide, briakinumab , traficet, AMG 827).
NOTE :Participants must not receive ustekinumab outside of the study or participate in an y other 
clinical study  with an investigational agent while in this study . If they intend to receive 
ustekinumab or participate in any other clinical study  with an investigational agent, an early 
termination visit should occur beforehand. The sponsor m ust be notified in advance (or as soon as 
possible thereafter) of any  instances in which prohibited therapi[INVESTIGATOR_23730].
6.6. Dose Modification
Dose/dosage adjustment of study  intervention isnot permitted within this study .
6.7. Intervention After the End of the Study
Participants will be instructed that study intervention will not be made available to them after they 
have completed or discontinued the stud y and that they should return to their primary ph ysician to 
determine the standard of care atthe end of the study  period .
7. DISCONTINUA TION OF STUDY INTERVENTI ON A ND PA RTICIPA NT 
DISCONTINUA TION OR WITHDRA WAL
7.1. Discontinuation of Study Intervention
A participant's study  intervention (ie, ustekinumab IV infusion and/or SC injection) must be
discontinue d if:
The investigator believes that for safety  or tolerability  reasons (eg,an adverse event) it is in 
the best interest of the participant to stop study  intervention .
The participant becomes pregnant , plans a pregnancy  within the study  period ,or plans a 
pregnancy  within 15weeks after the last study  intervention administration ; refer to 
Section 10.8 , Appendix 8for furth er information.
The participant is deemed ineligible according to the following TB screening criteria:
A diagnosis of active TB is made .
A participant has symptoms suggestive of active TB,based on follow -up assessment 
questions and/or physical examination , orhas had recent close contact [CONTACT_4490] a person with 
active TB, and cannot or will not continue to undergo additional evaluation.
A participant undergoing continued evaluation has a chest radiograph with evidence of 
current active TB and/or a positive Quan tiFERON -TB test result (or a positive tuberculin 
skin test result in countries in which the QuantiFERON -TB test is not approved/registered 
or the tuberculin skin test is mandated by [CONTACT_72952]) , unless active TB can 
be ruled out and appropria te treatment for latent TB can be initiated before the next 
administration of study  intervention and continued to comple tion. Participants who have 
an indeterminate result should have the test repeated. Participants with persistently 
indeterminate QuantiFERON -TB test results may continue without treatment for latent 
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 44
Approved , Date: [ADDRESS_493722] radiograph shows no abnormality  suggestive of 
TB (active or old, inactive TB) and the participant has no additional risk factors for TB 
as deter mined by [CONTACT_093]. This determination must be promptly  reported to the 
Sponsor’s medical monitor, recorded in the participant's source documents, and initialed 
by [CONTACT_093].
A participant receiving treatment for latent TB discontinues thistreatment prematurel y 
or is noncompliant with the therap y.
The participant experiences a serious adverse event related to either an injection or infusion. 
Discontinuation of ustekinumab administration must also be considered for participants who 
develop a non-serious but severe infusion or injection site reaction (as defined in Section 10.7 , 
Appendix 7).
The participant is diagnosed with amaligna ncy,including squamous cell skin cancer. 
Consideration may  be given to allow participants to continue to receive study  intervention if 
they develop 1 to 2basal cell skin cancers that are adequately  treated with no evidence of 
recurrence or residual disea se.
The participant initiates the following prohibited medications before Week 24:
Immunomodulatory  agents other than 6- MP, AZA or MTX .
Immunomodulatory  biologic agents.
Experimental or investigational Crohn ’sdisease medications.
The participant receives ustekinumab outside of the protocol.
A serious opportunistic infection occurs.
The participant withdraws consent for administration of study  intervention .
The participant is unable to adhere to the study  visit schedule or comply  with protocol 
requirements.
The participant has Crohn’s disease -related surgeries that precludes the ability  to further 
assess efficacy  through the CDAI . Surgeries that are thought to represent a lack of efficacy of 
study  intervention should be considered for discontinuation at the discretion of the investigator 
other than minor procedures (eg, placement of a seton or cutaneous drainage of an abscess) .
Consideration should also be given to discontinuing treatment in participants who show no 
evidence of therapeutic benefit 16 weeks af ter the IV re-induction.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 45
Approved , Date: [ADDRESS_493723] [ZIP_CODE].2. Participant Discontinuation/ Withdrawal From the Study
A participant will be withdrawn from the study  for any  of the following reasons:
Lost to follow -up.
Withdrawal of consent .
Death .
Sponsor decision (eg, receiving ustekinumab outside of the protocol or participating in any 
other clinical stud y with an investigational agent) .
Investigator decision (eg, because of an adverse event or lack of efficacy ).
Participants who terminate study  participation will not be required to return for any follow -up 
assessments butshould complete the safety  and efficacy evaluations specified for early withdrawal 
(see Schedule of Activities ) at the time they  terminate study participation. Additionally , the safet y 
follow upapproximately  20weeks after the last study  intervention administration, which may  be 
conducted at a site visit or by [CONTACT_756], applies to all participants, including those who 
discontinued study  intervention before Week [ADDRESS_493724] otherwise terminated study  
participation (eg, through withdrawal of consent), unless they  do not consent to this follow up by 
[CONTACT_3449] -site staff.
When a participant withdraws before completing the study , the reason for withdrawal is to be 
documented in the CRF and in the source document. Study  intervention assigned to awithdrawn 
participant may not be assigned to another participa nt. Participants who withdraw will not be 
replaced. If the reason for withdrawal from the study  is withdrawal ofconsent, then no additional 
assessments are allowed.
If a participant is withdrawn from the study  for any reason, the early termination assessm ents 
indicated in the Schedule of Activities should be performed as close as possible to the time of 
study  discontinuation . If the reason for withdrawal from the study  is withdrawal of consent, then 
no additional assessments are allowed.
7.2.1. Withdrawal From the Use of Research Samples
Aparticipant may withdraw consent for research samples, in which case the samples will be 
destroy ed,and no further testing will take place. To initiate the sample destruction process, the 
investigator must notify  the sponsor study  site contact [CONTACT_393393]. The sponsor study site contact [INVESTIGATOR_1318], in t urn, contact [CONTACT_393394]. If requested, the investigator will 
receive written confirmation from the sponsor that the samples have been destroy ed.
Aparticipant may also withdraw consent for use of samples infuture research (refer to Long -Term 
Retention of Samples for Additional Future Research in Section 10.6 ,Appendix 6). In such a case,
samples will be destro yed after they are no longer needed for the clinical study . Details of the 
sample retention for research are presented in the main I CF.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 46
Approved , Date: [ADDRESS_493725] the participant and determine the reason for discontinuation/withdrawal. The 
measures taken to follow up must be documented . Refer to Section 7.2for further details on 
participant discontinuation/withdrawal from the study .
8. STUDY ASSESSMENTS A ND PROC EDURES
Overview
The eligibility  of participants will be assessed during a 5- week screening period, at which written 
informed consent must be obtained prior to conducting any protocol -specific assessments or 
procedures. Study assessments will be conducted at baseline (Week 0) and at Weeks 8, [ADDRESS_493726] study  intervention 
administration (ie,Week 36 for participants who complete the final study  intervention visit at 
Week 16). The Schedule of Activities summarizes the frequency  and timing of safety , efficacy , 
ileocolonoscopy , PK, and immunogenicity measure ment sat screening and during the study .The 
following sections provide additional details on the evaluations to be conducted during the study .
During the screening period, participants will receive training in diary  card completion for 
recording CDAI and information on concomitant medications. For calculation of CDAI at Week 0, 
the hematocrit value obtained during screening will be used.
Where participants agree for this procedure, a baseline, video ileocolonoscopic evaluation should 
be performed within 14days before Week 0(see Section 8.1.7 ). An ileocolonoscopy  performed 
≤3months before baseline may be used as a measure of secondary  LoR(in combination with CDAI  
score; see Section 5.1, Inclusion Criterion 3), and may also be used as the baseline 
ileocolonoscopy ,provided a video r ecording of the procedure is available .For th ese participants, 
afinal endoscopy should be performed atthe Week 16 visit.
All study -specific PRO assessments should be conducted/ completed before any  tests, procedures, 
or other consultations to prevent in fluencing participant perceptions. The PRO instruments will be 
provided in the local language in accordance with local guidelines.
Study  site personnel must remind participants of the need to provide stool samples at the visits 
indicated in the Schedule of Activities.
All female participants of childbearing potential must have a negative serum pregnancy  test at 
screening and a negative urine pregnancy test at baseline and prior to each administration of study 
intervention. Additional serum or urine pregnancy  tests may be performed ,as determined 
necessary  by [CONTACT_393395], to establish the absence of 
pregnancy  at any  other time during study  participation.
The total blood volume to be collected from each participant will be approximately  180mL.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 47
Approved , Date: [ADDRESS_493727] be under the specified, and where applicable, controlled temperature conditions as indicated 
in the laboratory  manual.
Study -Specific Materials
The investigator will be provided with the following supplies:
Investigator's Brochure for ustekinumab.
EU SmPC /US P ackage Insert for ustekinumab .
Pharmacy Manual/Site I nvestigational Product and Procedures Manual .
Laboratory  Manual .
IWRS Manual .
Manual for electronic data capture (eDC) .
Sample I CF.
Contact [CONTACT_160220] .
Participant diary  cards.
Participant study  card.
Paper PRO questionnaires.
8.1. Efficacy  Assessments
8.1.1. Overview
The Schedule of Activities summarizes the frequency  and timing of efficacy  assessments during 
the study .
Efficacy  evaluations will include the following:
CDAI  (the primary  tool for assessing disease activity  response to ustekinumab) .
PRO -2 (the CDAI components of the total number of liquid or very soft stools and the 
abdominal pain score) .
IBDQ .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 48
Approved , Date: [ADDRESS_493728] 2020Inflammatory  markers including serum CRP and fCal.
Fistula assessment .
Endoscopic assessments of the intestinal mucosa based on the presence and absence of 
mucosal ulcerations and the SES -CD.
8.1.2. Crohn’s Disease A ctivity Index
The CDAI will be assessed by [CONTACT_393396] 8 specific Crohn’s disease -related 
variables4: extra -intestinal manifestations, abdominal mass, weight, hematocrit, total number of 
liquid stools, abdominal pain/crampi[INVESTIGATOR_007], use of antidiarrheal drug(s) and/or opi[INVESTIGATOR_858], and general 
well-being. The last four variables are scored over 7days by [CONTACT_137382] a diary  card.At 
each visit, the most recent hematocrit value before the current visit will be used for the calculation 
of CDAI.
For participants who agree for the ileocolonoscopy procedure , the CDAI should be completed 
before participants begin their preparation for this procedure, to prevent the ileocolonoscop y 
preparation from interfering with the CDAI  results. Ifileocolonoscopi[INVESTIGATOR_393367] [ADDRESS_493729] previous 7days not 
impacted b y the ileocolonoscopy and/or its preparation .
The PRO -2 includes the unweighted CDAI components of the total number of liquid or very  soft 
stools and the abdominal pain score .
Note : Fistulas that are only  visible during an ileocolonoscopy procedure should not be included in 
the calculation of the CDAI score , as fistulas seen only on endoscop y cannot be evaluated at all 
visits ( ie, not at Week 8 or Week 24).
A sample CDAI is presented in Section 10.10, Appendix 10.A standard weight table for CDAI is 
presented in Section 10.11 , Appendix 11.
8.1.3. C-reactive Protein
C-reactive protein has been demonstrated to be useful as a marker of inflammation in patients with 
inflammatory  bowel disease. In Crohn’s disease, elevated CRP concentrations have been 
associated with severe clinical activit y, elevated sedimentation rate, and active disease as detected 
by [CONTACT_19069] .24,30
Blood samples for the measurement of CRP will be collecte d from all participant s at visits 
indicated in the Schedule of Activities. C- reactive protein will be assay ed by [CONTACT_393397] a validat ed, high sensitivity  CRP assay .Results of postbaseline CRP measurement swill not 
be released to the inve stigators.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 49
Approved , Date: [ADDRESS_493730] [ZIP_CODE].1.4. Calprotectin
Fecal calprotectin has been demonstrated to be a sensitive and specific marker in identify ing 
intestinal inflammation and response to treatment in patients with inflammatory bowel disease.7
Stool samples for determination of fCal concentration swill be collected from all participant s at 
visits indicated in the Schedule of Activities ; those s tool samples should not be collected on days 
impacted b y ileocolonoscopy preparation.
The assay  for fCal concentration will be performed using a validated method by [CONTACT_11378] . Additional tests may also be performed on the stool samples for additional markers 
related to intestinal inflammat ion and treatment response. Results of post-baseline fCal tests will 
not be released to the investiga tors.
8.1.5. Inflammatory  Bowel Disease Questionnaire
The IBDQ14is a validated, 32-item self-report questionnaire for participants with inflammatory
bowel disease to evaluate PROs across 4dimensions: bowel symptoms (loose stools, abdominal 
pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need 
to cancel social events), and emotional function (anger, depression, irritability ). Scores range from 
32 to 224, with higher scores indicating better outcomes.
The IBDQ should be administered before an y other study -specific procedures are performed.
Participants who do not remain in the study  at Week 16, due to discontinuation of study  
intervention and/or termination of study  participation, should have their follow -up IBDQ at the 
early termination visit.
A sample IBDQ is presented in Section 10.12 , Appendix 12.
8.1.6. Fistula A ssessment
All participant swill be assessed for fistulas. For participant s with fistulizing disease, fistula closure 
will be assessed. Enterocutaneous fistulas (eg, perianal and abdominal) will be considered no 
longer draining (ie, closed) when there is absence of draina ge despi[INVESTIGATOR_393368]. 
Rectovaginal fistulas will be considered closed based on either physical examination or absence 
of relevant s ymptoms (eg, passage of rectal material or flatus from the v agina). Only  those fistulas 
that can be assessed during a normal ph ysical examination should be included as part of the fistula 
assessment.
8.1.7. Video Ileocolonoscopy
At the ph ysician’s discretion ,where participants agree for this procedure, ileocolonoscop yshould 
be performed at baseline and at Week 16, for exploratory assessment of SES -CD and to determine 
the presence or absence of mucosal inflammation and ulceration.
All ileocolonoscopi[INVESTIGATOR_393369]. The 
baseline (Week 0)ileocolonoscopy  should be performed within 14days before or at the Week 0 
visit. The Week 16ileocolonoscopy  should be performed within 14days before or 28 days after 
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 50
Approved , Date: [ADDRESS_493731] 2020the Week 16visit. Where ileocolonoscop y impacts the 7days used for CDAI evaluations, see 
Section 8.1.2 for details on how those CDAI scores should be calculated.
Participants who do not remain in the study  at Week 16(due to discontinuation of study  
intervention and/or termination of study  participation) should have their follow -up 
ileocolonoscopy  at the early  termination visit , where possible .
Theileocolonoscop y procedures should be video -recorded , followi ng the more detailed directions 
provided in the separate study  reference (or ileocolonoscopy ) manual. Video endoscopi[INVESTIGATOR_393370] b y a central facility  that will be blinded to intervention group .
SES-CDScoring System
The SES-CD scoring s ystem, which ranges from 0 to 60, includes 4 variables, each considered in 
5 segments of the bowel (the ileum, ascending colon, transverse colon, descending colon, and 
rectum):
Ulcer size: 0.1–0.5 cm; 0.5 –2 cm; >2 cm .
Extent of ulcerated surface: <10%; 10% –30%; >30%.
Extent of affected surf ace: <50%; 50% –75%; > 75%.
Stenosis: Single or multiple and partially  or totall y occluded.
8.2. Safety  Assessments
Safety  and tolerabilit y evaluations will be performed as summarized in the Schedule of Activities.
In cases of self -administration of SC study intervention , participants are requested to contact [CONTACT_393398] o f an adverse event.
Adverse events will be reported and followed b y the investigator as specified in Section 8.3and in 
Section 10.[ADDRESS_493732] be recorded inthe adverse e vent 
section of the CRF.
Any clinically  significant abnormalities persisting at the end of the study/early withdrawal will be 
followed b y the investigator until resolution or until a clinically  stable condition is reached.
8.2.1. Physical Examination
Physical examinations will be performed as specified in the Schedule of Activities. Any 
abnormalities or changes in severit y noted during the review of body  systems should be 
documented in the source document .
8.2.2. Vital Signs
Vital signs (temperature, pulse/heart rate, and systolic and diastolic blood pressure )will be 
obtained immediatel y before the initial IV infusion, approximately  every 30minutes during the IV 
infusion, and twice (at approximately  30-minute intervals) after the completion of the IV infusion. 
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 51
Approved , Date: [ADDRESS_493733] be filed with the source documents.
For some tests related to screening criteria, existing local or central laboratory  results are 
acceptable to satisfy  study requirements (eg, QuantiFERON -TB test, stool pathogens) provided 
they were performed in the required time windows. Appropriateness may be discussed with the 
medical monitor.
8.3. Adverse Events and Serious A dverse Events
Timely, accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial forthe protection of participants, investigators, and the sponsor, and are mandated by 
[CONTACT_23824]. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporti ng of safet y 
information; all clinical studies conducted by [CONTACT_43765].
Adverse events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, 
or the par ticipant's legally  acceptable representative) for the duration of the study .
Anticipated events will be recorded and reported as described in Section 10.4, Appendix 4.
For further details on adverse events and serious advers eevents (definitions and classifications; 
attribution definitions; severity criteria; special reporting situations; procedures) as well as product 
quality  complaints, refer to Section 10.7 , Appendix 7.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 52
Approved , Date: [ADDRESS_493734] [ZIP_CODE].3.1. Time Period and Frequency  for Collecting A dverse E vent and S erious 
Adverse E vent Information
All Adverse Eve nts
All adverse events and special reporting situations, whether serious or non-serious, will be reported 
from the time a signed and dated ICF is obtained until completion of the participant's last study -
related procedure, which may include contact [CONTACT_20687]-up of safety . Serious adverse events, 
including those spontaneously  reported to the investigator within [ADDRESS_493735] dose of 
study  intervention (ie, up to Week36), must be reported using the Serious Adverse Event Form. 
The sponsor will evaluate any safety information that is spontaneousl y reported by [CONTACT_170186].
Serious Adverse Events
All serious adverse events occurring during the study  must be reported to the appropriate sponsor 
contact [CONTACT_9702] b y stud y-site personnel within [ADDRESS_493736] be completed and signed by a ph ysician from the study  site and
transmitted to the sponsor within 24hours. The initial and follow -up reports of a serious adverse 
event should be made b y facsimile (fax) .
8.3.2. Method of Detecting A dverse E vents and S erious Adverse E vents
Care will be taken not to introduce bias when detecting adverse events or serious adverse events. 
Open -ended and nonleading verbal questioning of the participant is the preferred method to inquire 
about adverse event occurrence.
Solicited Adverse Events
Solicited adverse events arepredefined local and systemic events for which the participant is 
specificall y questioned, and which are noted by  [CONTACT_160226] .
Unsolicited Adverse Events
Unsolicited adverse events are adverse events for which the participant is not specificall y 
questioned in the participant diary .
8.3.3. Follow -up of A dverse E vents and S erious Adverse E vents
Adverse events, including pregnancy , will be followed by [CONTACT_393399] 10.7 ,Appendix 7.
8.3.4. Regulatory  Reporting Requirements for S erious Adverse E vents
The sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory 
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs). For 
anticipated events reported as individual serious adverse events the sponsor will make a 
determination of relatedness in addition to and independent of the inve stigator’s assessment. The 
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 53
Approved , Date: [ADDRESS_493737] 2020sponsor will periodically  evaluate the accumulating data and, when there is sufficient evidence and 
the sponsor has determined there is a reasonable poss ibility  that the intervention caused a serious 
anticipated event, they  will submit a safety  report in narrative format to the investigators (and the 
head of the institute where required ). The sponsor assumes responsibility  for appropriate reporting 
of anticipated events to the regulatory  authorities according to requirements of the countries in 
which the studies are conducted .
8.3.5. Pregnancy
All initial reports of pregnancy  in female participants or partners of male participants must be 
reported to the sponsor by [CONTACT_1758] -site personnel within 24 hours of their knowledge of the event 
using the appropriate pregnancy  notification form. Abnormal pregnancy  outcomes 
(eg,spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy ) are 
considered serious adverse events and must be reported using the Serious Adverse Event Form. 
Any participant who becomes pregnant during the study  must discontinue further study 
intervention .Follow -up information regarding the outcome of the pregnancy  and anypostnatal
sequelae in the infant will be required .
8.3.6. Infusion/Injection Site Reactions and A llergic Reactions
Infusion Reactions
An infusion reaction is defined as an adverse event that occurs during or within 1 hour following 
the infusion of study  interven tion, with the exception of laboratory  abnormalities. Minor infusion 
reactions may be managed by [CONTACT_247915]/or treating with 
antihistamines and/or acetaminophen (paracetamol) as clinically  indicated. If an IV infusion of 
study  intervention is stopped because of an infusion reaction and the reaction, in the opi[INVESTIGATOR_1070], is not severe or does not result in a serious adverse event, the infusion may be restarted 
with caution.
Injection Site Reaction s
An injection site reaction is any adverse reaction at a study  intervention injection site. The injection 
sites will be evaluated for reactions and an y injection site reactions will be recorded as an adverse 
event.
Allergic Reactions
Before IV infusion, appropriately  trained personnel and medications to treat allergic reactions, 
including anaph ylaxis, must be available. Appropriate medical personnel must be in attendance at 
the time of the infusion and for at least [ADDRESS_493738] be observed carefully  for symptoms of an allergic reaction ( eg, 
urticaria, itching, hives).
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 54
Approved , Date: [ADDRESS_493739] 2020If a mild or moderate allergic reaction is observed, acetaminophen, NSAIDs, and/or 
diphenhy dramine may  be administered. In the case of a severe allergic reaction (eg, anaph ylaxis), 
SC aqueous epi[INVESTIGATOR_238], corticosteroids, respi[INVESTIGATOR_356307], and other proper resuscitative 
measures are essential and must be available at the study  site where the infusion or injections are 
being given.
Participants who receive an incomplete administration of the IV dose, due to any safet y 
observation requiring intervention, should be discontinued from further injections of study 
intervention .
Participants who experience any systemic reaction following an IV infusion or SC injection of 
ustekinumab that requires ventilatory  support or treatment with epi[INVESTIGATOR_393371].
8.3.7. Infections
Study  intervention should not be administered to a participant with a clinically  important, active 
infection. Investigators are required to evaluate participants for any signs or symptoms of infection, 
and also review participants’ diary  cards for signs of infection, at scheduled visits.
If a participant develops a serious infection, including but not limited to sepsis or pneumonia, 
discontinuation of study  treatment must be considered. For active varicella -zoster infection or a 
significant exposure to varicella -zoster infection in a participant without a history  of chickenpox, 
study  intervention should be interrupted until the symptoms have resolved an d no active infection 
is present.
Assessments for TB infection will be performed at the visits specified in the Schedule of Activities. 
Refer to Section 10.3, Appendix 3fordetails of tuberculin skin testing.
8.3.8. Malignancies
Any participant who develops a malignancy ,including squamous cell skin cancer , will be 
withdrawn from study  intervention . Consideration m ay be given to allow participants who develop 
1 to 2basal cell skin cancers to continue to receive study  intervention if they are adequatel y treated 
with no evidence of recurrence or residual disease.
8.3.9. Disease -Related Events andDisease -Related Outcomes Not 
Qualify ing as A dverse Eventsor Serious Adverse E vents
All events that meet the definition of a serious adverse event will be reported as serious adverse 
events, regardless of whether they  are protocol -specific assessments or not .
8.4. Treatment of Overdose
Single IV doses of ustekinumab up to approximately  6 mg /kg have been administered in clinical 
studies without dose-limiting toxicity . In case of overdose, it is recommended that the patient be 
monitored for an y signs or symptoms of adverse reactions or eff ects and appropriate s ymptomatic 
treatment be instituted immediately .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 55
Approved , Date: [ADDRESS_493740] be drawn PRIOR to the administration 
of ANY study  intervention (IV or SC), except forthe Week [ADDRESS_493741] be drawn before ANY study  intervention (IV or SC) 
and approximately  60minutes after completion of the IV infusion. At all other times, blood 
samples should be collected before administration of study  intervention.
With the exception of the post- infusion blood sample at Week 0, which will be for PK evaluation 
only, each serum sample will be divided into 3 aliquots (1 each for pharmacokinetics, antibodies 
to study  intervention , and a back -up sample) .
8.5.2. Analytical Procedures
All PK serum samples collected will be evaluated by a central laboratory  for ustekinumab serum 
concentration sand anti-ustekinumab antibodies to enable interpretation of the data.
Pharmacokinetics
Serum concentrations of ustekinumab will be determined using a validated, specific, and sensitive 
method by  [CONTACT_43754].
Immunogenicity
The detection and characterization of anti-ustekinumab antibodies will be performed using a 
validated , drug -tolerant assay  method by  [CONTACT_393400].
8.5.3. Pharmacokinetic Parameters and Evaluations
Serum samples will be used to evaluate various pharmacokinetic parameters, including trough and 
peak ustekinumab concentrations.
8.6. Genetics
Pharmacogenomics orother genetic measures arenot evaluated in this study.
8.7. Medical Resource Utilization and Health Economics
Medical Resource Utilization and Health Economics parameters are not evaluated in this study .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 56
Approved , Date: [ADDRESS_493742] [ZIP_CODE].8. Biomarkers
Biomarker assessments will be conducted to examine the biologic response to treatment and to 
identify  biomarkers that are relevant to ustekinumab treatment and/or Crohn’s disease . 
Assessments may include the evaluation of relevant biomarkers in serum, blood, and/or stool 
samples collected as specified in the Schedule of Activities. Data collected from these samples 
will be used for exploratory  research , which will include the following objectives:
To understand the molecular effects of ustekinumab.
To understand thepathogenesis of Crohn’s disease.
To develop new laboratory  tests that could be used clinicall y in Crohn’s disease or other 
conditions.
Genetic analyseswill not be performed on biological samples obtained for this study .
8.8.1. Serum- based Biomarkers
Blood sam ples for serum -based biomarker analyseswill be collected from all participants. Assays 
to be performed may include proteins associated with proinflammatory  and anti-inflammatory  
effects, the recruitment and proliferation of cells associated with inflammat ion and repair, and 
markers associated with tissue injury  or repair.
8.8.2. Whole Blood -based Biomarkers
Whole blood samples will be collected from all participants to assess the effect of study 
intervention on RNA expression profiles. Whole blood analy ses may also examine RNA 
expression associated with the pathogenesis of Crohn’s disease.
9. STATISTICA L CONSIDERA TIONS
Statistical analy sis will be conducted by [CONTACT_43758]. A 
general description of the statistical methods to be used to analy ze the efficacy  and safet y data is 
outlined below. Specific details will be provided in the s tatistical analysis plan.
9.1. Statistical Hy pothesis
The study  hypothesis is that in patients with secondary  LoR to SC q8w 90 mg ustekinumab
maintenance treatment , a single weight -tiered based IV re -induction dose of 6mg/kg ustekinumab 
will result in a higher clinical response rate (defined as a ≥100- point reduction from the baseline 
CDAI  score, or a CDAI score <150) after 16 weeks of treatme nt, compared with continuous SC 
q8w 90 mg ustekinumab maintenance treatment.
It is expected that the difference in the proportion of participants who achieve a clinical response 
after receiving the 6mg/kg IV re-induction of ustekinumab compared with participants receiving 
continuous SC q8w [ADDRESS_493743] 20percentage 
points. The study  is powered based on this difference in the level of response.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 57
Approved , Date: [ADDRESS_493744] [ZIP_CODE].2. Sample Size Determination
The assumptions that form the basis for sample size and power calculations incorporated into this 
protocol to support the primary  endpoint arebased on the dose adjustment data from the IMUNIT I 
Phase 3 study . In I MUNITI , 17of 29 (59%) participant s attaine d clinical response 16 weeks after 
LoR in the q12w adjusted to q8w group, while 11of 28 (39%) participants attained clinical 
response 16 weeks after LoR in the sham dose adjustment group (ie. contin ually  remaining on SC 
q8w dosing). The hypothesis for thesample size determination is that the IV ustekinumab group
in this study  will perform similarly to, if not better than, theq12w adjusted to q8w group in the 
IMUNITI study, given that the participants in this group will receive a higher dose of ustekinumab 
than those in the I MUNITI  study , who received an adjustment from q12w to q8w.
Assuming a 60% clinical response rate at Week 1 6 in the ustekinumab IV re-induction group and 
40% in the continuous SC q8w 90mg group, 100 participants per interventi on group will y ield an 
overall power above 80%, at a significance level of 0.05 ([ADDRESS_493745] ).
Table 2provide sthe power for detecting a treatment difference between the IVustekinumab group
and the continuous SC q8w 90mg ustekinumab group (for 100 participant s per group) under 
varying assump tions for the clinical response rates .
Table 2: Power to Detect a Treatm ent Effect Based on Different P roportions of Participant s Achieving 
Clinical Response at Week 16 (Each G roup)
Clinical response at Week 16 (%)
SC q8w  90 mg
(n=100)IV re -induction
(n=100)Power
40% 55% 59%
- 60% 83%
- 65% 95%
9.3. Populations for A nalysis
For purposes of analy sis, the following populations are defined:
Table 3: Populations for Analysi s
Population Description
Intent -to-treat population
(ITT)All participants randomized to 1of the 2intervention group s.
Treated population
(safety, PK)All participants in the ITT population who receive at least one dose of 
study intervention.
9.4. Statistical A nalysis
9.4.1. Efficacy  Analysis
Efficacy  analyseswill be based onan intent -to-treat principle ; the efficacy  data for each participant 
will be anal yzed according to the assigned treatment regardless of the actual treatment received.
For the primary  endpoint, the proportion of participants in clinical response at Week 16 will be 
compared between the IV group and the continuous SC q8w group using a 2- sided 
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 58
Approved , Date: [ADDRESS_493746], stratified by [CONTACT_393379] ( ≤300 or >300) and 
prior biologic failure status at baseline (y es or no) at a significance level of 0.05.
Participants with missing data, defined as those who terminate the study  before the designated visit 
or participants who have a missing value at the designa ted visit, will be considered to not have 
achieved their dichotomous efficacy  endpoints. For continuous endpoints, the last available value 
will be carried forward for participants with missing data.
Treatment failure rules will override the response status (eg, clinical response, clinical remission, 
and mucosal healing). Participants who meet any of the following criteria for treatment failure will 
be considered to not have achieved their dichotomous efficacy  endpoints from the time the 
treatment failure occurs onwards:
Had a Crohn’s disease -related surgery  due to lack of efficacy ; OR
Discontinued study intervention due to an adverse event of worsening Crohn’s disease or due 
to lack of efficacy ; OR
Had a prohibited change in concomitant medications (to be detailed in the statistical analysis 
plan).
For continuous efficacy  endpoints, the baseline value will be carried forward from the time the 
treatment failure occurs onwards.
The study  endpoints (as listed in Section 3) will be compared between the IV group and the 
continuous SC q8w group. Analy sessuitable for categorical data (eg ,chi-square test or Cochran -
Mantel -Haenszel chi-square test, as appropriate) will be used to compare the proportion of 
participants achieving selected endpoints (eg, clinical remission) between the IV group and the 
continuous SC q8w group. In the case of rare events, Fisher’s exact test will be used for treatment 
comparisons. Continuous variables will be compared between the IV group and the continuous SC 
q8w group using an analysis of variance/covariance.
9.4.2. Safety  Analysis
Safety  will be assessed through Week [ADDRESS_493747] study  intervention 
administration (ie,Week 36 for participants who complete the final study  intervention visit at 
Week 16). All participants who receive at least 1 administration of study  intervention will be 
included in the safet y analy ses. Participants will be analyzed according to the actual treatment 
received.
Adverse Eve nts
The verbatim terms used in the CRF by [CONTACT_393401] (MedDRA). Intervention -emergent adverse 
events are adverse events with onset during the intervention phase or that are a consequence of a 
pre-existing condition that has worsened since baseline. All reported adverse events will be 
included in the analy sis. For each adverse event, the percentage of participants who experience at 
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 59
Approved , Date: [ADDRESS_493748] 1occurrence of the given event will be summarized by [CONTACT_65237] . In addition, 
comparisons between intervention group s will be provided if appropriate.
Summaries, listings, datasets, or participant narratives may  be provided, as appropriate, for those 
participants who die, who discontinue intervention due to an adverse event, or who experience a 
severe or a serious adverse event.
Adverse events will be assessed b y evaluating summaries of the following:
Adverse events .
Serious adverse events.
Reasonabl y related adverse events (very  likely, probable, possible ,as assessed by [CONTACT_1275]) .
Discontinuation of study  intervention due to adverse event(s) .
Adverse events of clinical interest:
Injection site reactions .
Infusion -related adverse events (during or within 1 hour of theIV infusion) .
Infections and serious infections.
Malignancies.
Clinical Laboratory Tests
The following clinical laboratory  measures will be used to assess the safety  of participants:
Laboratory  parameters (hematology  and chemistry ) and change from baseline in these 
laboratory  parameters.
The incidence of markedly  abnormal laboratory  parameters.
Definitions for markedl y abnormal results for each laboratory  parameter will be defined in the 
statistical analysis plan.
9.4.3. Other Analyses
Pharmacokinetic Analyses
Descriptive statistics of serum ustekinumab concentrations will be calculate d at each sampling 
time point. Serum ustekinumab concentrations over time will be summarized separately  for the 
ustekinumab IV group and the continuous maintenance group .
Concentrations below the lowest quantifiable concentration will be treated as zero in the summary 
statistics.
Immunogenicity Analyses
The incidence of anti -ustekinumab antibodies will be summarized for all participants who have at 
least one sample obtain ed after their first dose of ustekinumab for detection of antibodies to 
ustekinumab.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 60
Approved , Date: [ADDRESS_493749] 2020Pharmacokinetic/Pharmacodynamic Analyses
Analysesof the PK, immunogenicity , and pharmacody namics of study  intervention will include:
Characterization of the PK and im munogenicity  of ustekinumab in participants.
Assessment of the relationship between s ystemic ustekinumab exposure and:
clinical outcomes, including CDAI measures.
changes in CRP and fCal.
endoscopic outcomes.
Correlation of the PK data in this study  with the PK data of the UNITI trials.
9.5. Interim A nalysis
Aninterim analy sis will be performed in the study after [ADDRESS_493750] ician who is not part of the study  team .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 61
Approved , Date: [ADDRESS_493751] 202010. SUPPORTING DOCUMENTA TION A ND OPERA TIONA LCONSIDERA TIONS
10.1. Appendix 1: Abbrev iations and Definition of Terms
Abbreviations
ALT Alanine aminotransferase
5-ASA 5-aminosalicylic acid
AST Aspartate aminotransferase
AZA Azathioprine
BCG Bacille Calmette -Guérin
CDAI Crohn’s Disease Activity Index
Cmax Maximum serum concentration
CRF Case report form
CRP C-reactive protein
eDC Electronic data capture
EU European Union
fCal Fecal calprotectin
FSH Follicle stimulating hormone
GCP Good Clinical Practice
-hCG -human chorionic gonadotropin
HRT Hormonal replacement therapy
IBDQ Inflammatory Bow el Disease Questionnaire
ICF Informed consent form
ICH International Conference on Harmonisation
ICMJE International Committee of Medical Journal Editors
IgG1k Human immunoglobulin G1 kappa
IL Interleukin
ITT Intent -to-treat
IV Intravenous
IWRS Interactive web response system
LoR Loss of response
MedDRA Medical Dictionary for Regulatory Activities
6-MP 6-merc aptopurine
MTX Methotrexate
PFS Prefilled syringe(s)
PK Pharm acokinetic(s)
[COMPANY_003] Purified protein derivative
PQC Product quality complaint
PRO Patient -reported outcome
qXw Every Xweeks (where X=4, 8 or 12)
SC Subcutaneous
SES-CD Simple endoscopic score for Crohn’s disease
SmPC Summary of Product Characteristics
S[LOCATION_003]R Suspected unexpected serious adverse reactions
TB Tuberculosis
TNF Tumor necrosis factor
TU Tuberculin units
US [LOCATION_002]
WBC White blood cell
Definition of Terms
Study intervention Ustekinumab administered as an 6mg/k gIV infusion or a 90mg SC injection .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 62
Approved , Date: [ADDRESS_493752] 202010.2. Appendix 2: Definition of Ustekinumab Initial Response andCurrent 
Therapy
Eligible participants must:
Be on SC [ADDRESS_493753] 
2doses of per label SC 90 mg ustekinumab treatment 8weeks apart .
AND
Have demonstrated previous clinical remission OR previous clinical response within 
20weeks after receiving ustekinumab induction therap y given as a single IV dose of ~6mg/kg 
followed by 90mg SC injection at Week 8, based oneither the clinical remission or clinical 
response criteria specified below.
Note: Participants may have initially  received SC 90mg q12w maintenan ce and subsequentl y 
escalated to SC [ADDRESS_493754] demonstrated previous 
clinical remission OR previous clinical response within 20weeks after initiation of 
ustekinumab induction therap y, as above .
Evidence of previous ustekinumab doses and measures of initial response or remission should be 
documented by [CONTACT_30219], letter provided by a referring physician, patient diaries, reliable 
patient history  with subsequent documentation or by [CONTACT_39785] ‘reason for referral’ documents 
(eg,insurance authorization forms), if available, and recorded in the eCRF. If such documentation 
is not available, investigators can confirm the ustekinumab doses and initial response/remission in 
the eCRF according to their best knowledge and cli nical judgement.
Evidence of Clinical Remission to Ustekinumab Treatment:
Any of the following available criteria should be documented and noted in the eCRF:
Documented CDAI <150 (if score is available) .
Documented Harvey  Bradshaw Index of <5 (if score is available) .
No more than mild abdominal pain with 3or less soft or loose stools per day ,on average, for 
at least a 1 -week period .
No abdominal pain, with an average of 5or less soft or loose stools per day, for at least a 
1-week period.
Evidence of Clin ical Response to Ustekinumab Treatment:
Any of the following available criteria should be documented and noted in the eCRF:
PROs:
Reduction of [ADDRESS_493755] 70 points in overall CDAI 
score, if documentation of these scores are available .Where documented in a patient’s medical 
records, the scores for the individual components of these indexes should also be recorded.
Meaningful reduction of stool frequency .
Reduction of rectal bleeding .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 63
Approved , Date: [ADDRESS_493756] 2020Meaningful r eduction of daily  abdominal pain/discomfort .
Resolution ofone or more extra -intestinal manifestations (eg arthralgia, pyoderma 
gangrenosum, etc) .
Objective Measures of Disease Activity:
Resolution of drainage from prior draining fistula (s).
Improvement in ileocolonoscopy (resolution of all ulcerations in at least one ileocolonic 
segment ).
Normalization of CRP (<3mg/L ) or fCal (<250 mg/kg) in participants with elevated 
CRP/ fCal at initiation of ustekinumab.
Reduction in steroid dose (or elimination of corticosteroids) after initiation of ustekinumab.
Acceptable documentation
Evidence of previous ustekinumab doses and measures of initial response or remission should be 
documented by [CONTACT_30219], letter provided by a referring physician, patient diaries, reliable 
patient history  with subsequent documentation or by [CONTACT_39785] ‘reason for referral’ documents 
(eg,insurance authorization forms) , if available. If such documentation is not available, 
investigators can confirm the ustekinumab doses and initial response/remission in the eCRF 
according to their best knowledge and clinical judgement .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 64
Approved , Date: [ADDRESS_493757] 202010.3. Appendix 3: Tuberculin Skin Testing
Administering the Mantoux Tuberculin Skin Test
The Mantoux tuberculin skin test (CDC, 2000) is the standard method of identify ing persons 
infected with Mycobacterium tuberculosis. Multiple puncture tests (Tine and Heaf) should not be 
used to determine whether a person is infected because the amount of tuberculin injected 
intradermall y cannot be precisel y controlled . Tuberculin skin testing is both safe and reliable 
throughout the course of pregnancy . The Mantoux tuberculin test is performed by [CONTACT_41058] 0.1mL of tuberculin into the inner surface of the forearm . The test must 
be performed with tuberculin that has at least the same strength as either 5tuberculin units (TU) 
of standard purified protein derivative ([COMPANY_003]) -S or 2TU of [COMPANY_003]-RT23, Statens Seruminstitut, as 
recommended by [CONTACT_38375]. [COMPANY_003] strengths of 1TU or 250TU are not 
acceptable (Menzies, 2000). Using a disposable tuberculin syringe with the needle bevel facing 
upward, the injection should be made just beneath the surface of the skin. This should produce a 
discrete, pale elevation of the skin (a wheal) 6 mm to 10 mm in diam eter. To prevent needle -stick 
injuries, needles should not be recapped, purposely  bent or broken, removed from disposable 
syringes, or otherwise manipulated by  [CONTACT_35681] . After they  are used, disposable needles and sy ringes 
should be placed in puncture -resistant containers for disposal. Institutional guidelines regarding 
universal precautions for infection control (eg, the use of gloves) should be followed. A trained 
health care worker, preferably  the investigator, should read the reaction to the Mantoux test [ADDRESS_493758], tuberculin testing should be repeated . The area of induration (palpable 
raised hardened area) around the site of injection is the reaction to tuberculin . For standardization, 
the diameter of the induration should be measured transversel y (perpendicular) to the long axis of 
the forearm . Erythema (redness) should not be measured . All reactions should be recorded in 
millimeters, even those classified as negative.
Interpreting the Tu berculin Skin Test Results
In the US and many  other countries, the most conservative definition of positivity  for the tuberculin 
skin test is reserved for immunocompromised participant s, and this definition is to be applied in 
this study  to maximize the li kelihood of detecting latent TB, even though the participants may not 
be immunocompromised at baseline.
In the US and Canada, an induration of [ADDRESS_493759] be followed.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 65
Approved , Date: [ADDRESS_493760] be followed.
References
Centers for Disease Control and Prevention. Core curriculum on tuberculosis: What the clinician should know 
(Fourth Edition) . Atlanta, GA: Department of Health and Human Services; Centers for Disease Control and 
Prevention; National Center for HIV, STD, and TB Prevention; Division of Tuberculosis Elimination; 2000:25 -86.
Menzies RI . Tuberculin skin testing. In: Reichman LB, Hershfield ES (eds). Tuberculos is, a comprehensive 
international approach. 2nd ed . New  York, NY: Marcel Dekker, Inc; 2000:279 -322.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 66
Approved , Date: [ADDRESS_493761] 202010.4. Appendix 4: Anticipated Events
Anticipated Event
An anticipated event is an adverse event (serious or non-serious) that commonl y occurs as a 
consequence of the underly ing disease or condition under investigation (disease related) or 
background regimen.
For the purposes of this study  the following events will be considered anticipated events:
Adverse Events Associated with the Stud y Population
 Adverse events related to symptoms of Crohn’s disease .
 Adverse events related to worsening or progression of Crohn’s disease .
Reporting of Anticipated Events
All adverse events will be recorded in the CRF regardless of whether considered to be anticipated 
events and will be reported to the sponsor as described under ‘All Adverse Events ’in Section 8.3.1 . 
Any anticipated event that meets the serious adverse event criteria will be reported to the sponsor 
as described under ‘Serious Adverse Events ’in Section 8.3.1 . These anticipated events are exempt 
from expedited reporting as individual single cases to health authorities; however, if based on an 
aggregate review, it is determined that an anticipated event is possibly  related to study intervention , 
the sponsor will report these events in an expedited manner.
Anticipated Event Review Committee
An Anticipated Event Review Committee will be established to perform reviews of pre -specified 
anticipated events at an aggregate level. The Anticipated Event Review Committee is a safety  
committee within the sponsor’s organization that is independent of the sponsor’s study  team and 
will meet to aid in the recommendation to the sponsor’s study  team as to whether there is a 
reasonable possibility  that an anticipated event is related to the study  intervention .
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency  of review and threshold 
to trigger an aggregate analy sis of anticipated events will be provided in a separate Anticipated
Events Safet y Monitoring Plan.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 67
Approved , Date: [ADDRESS_493762] 202010.5. Appendix 5: Clinical Laboratory  Tests
The following tests will be performed by a central laboratory , unless otherwise specified or 
approved b y the medical monitor:
Follicle stimulating hormone (for assessment of postmeno pausal state, where applicable).a
Stool sample tests for enteric pathogens .a
Stool fecal calprotectin .
Serum C -reactive protein .
Serum pregnancy  testing for women of childbearing potential.
Serology  for HIV antibody , HBsAg, anti-HBs, anti -HBc, hepatitis C virus antibody .a
aFor some tests related to screening criteria, existing local or central laboratory results are acceptable to satisfy 
study requirements provided they were performed in the required time windows. Appropriateness of such tests 
may be discussed w ith the medical monitor.
Hematology :
-hemoglobin
-hematocrit (to enable CDAI evaluations)
-WBC count with differential
-platelet count
Serum Chemistry :
-sodium -total and direct bilirubin
-potassium -alkaline phosphatase
-chloride -calcium
-blood urea nitrogen /urea -phosphate
-creatinine -albumin
-aspartate aminotransferase (AST) -total protein
-alanine aminotransferase (ALT)
Hematology  and clinical chemistry  tests should be repeated at Week 0 if the screening tests were 
done >2 weeks previously .
The following tests will be performed by [CONTACT_393402] , unless otherwise specified or approved 
by [CONTACT_7195] :
Urine pre gnancy  testing for women of childbearing potential.
If required, SARS -CoV -2 (COVID -19) test may be performed at a local lab (per Exclusion 
Criterion 27).
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 68
Approved , Date: [ADDRESS_493763] 202010.6. Appendix 6: Regulatory , Ethical, and Study Oversight Considerations
REGULATORY AND ETHICAL CONSIDERATIONS
Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice, and applicable regulatory  and country -
specific requirements.
Good Clinical Practice is an international ethical and scientific quality  standard for designing, 
conducting, recording, and reporting studies that involve the participation of human participants. 
Compliance with this standard provides public assurance that the rights, safety , and well -being of 
study  participants are protected, consistent with the principles that originated in the Declaration of 
Helsinki, and that the study  data are credible.
Protocol Amendments
Neither the inve stigator nor the sponsor will modify this protocol without a formal amendment b y 
the sponsor. All protocol amendments must be issued by  [CONTACT_393403]. Protocol amendments must not be implemented without prior IEC/IRB approval, or 
when the relevant competent authority  has raised any grounds for non-acceptance, except when 
necessary  to eliminate immediate hazards to the participants, in which case the amendment must 
be promptly  submitted to the IEC/IRB and relevant compe tent authority . Documentation of 
amendment approval by  [CONTACT_23846]/IRB must be provided to the sponsor. When the 
change(s) involve only logistic or administrative aspects of the study , the IEC/IRB (where 
required) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact [CONTACT_90814](s), which will be p rovided as a separate document. Except 
in emergency  situations, this contact [CONTACT_393404]. In all cases, contact [CONTACT_90816]. The data recorded in the CRF and source 
documents will reflect any departure from the protocol, and the source documents will describe 
this departure and the circumstances requiring it.
Regulatory Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A  study may not be initiated until all local regulatory 
requirements are met.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 69
Approved , Date: [ADDRESS_493764] be provided to the sponsor before shipment of study  intervention
to the study  site:
 Protocol and amendment(s), if an y, signed and dated by [CONTACT_458] .
 A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, participant compensation programs. This approval must clearly identify  the 
specific protocol by [CONTACT_23850] (or sealed, where appropriate per 
local regulations) b y the chairman or authorized designee.
 Name [CONTACT_23875]/IRB, including a current list of the IEC/IRB members and their 
function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, from 
the IEC/I RB, a general statement may be substituted for this list. If an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the vote/opi[INVESTIGATOR_66821] .
 Regulatory  authority  approval or notification, if applicable .
 Signed and dated statement of investigator (eg, Form FDA 1572), if applicable .
 Documentation of investigator qualifications (eg, curriculum vitae).
 Completed investigator financial disclosure form from the principal investigator, where 
required .
 Signed and dated Clinical Trial A greement, which includes the finan cial agreement.
 Any other documentation required by  [CONTACT_427].
The following documents must be provided to the sponsor before enrollment of the first 
participant:
 Completed investigator financial disclosure forms from all subinvestigators .
 Document ation of subinvestigator qualifications (eg, curriculum vitae).
 Name [CONTACT_23876] , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable .
 Local laboratory  documentation demonstrating competence and test reliabilit y 
(eg,accreditation/license), if applicable.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 70
Approved , Date: [ADDRESS_493765]
Before the start of the study , the investigator (or sponsor where required) will provide the IEC/IRB 
with current and complete copi[INVESTIGATOR_23747] (as required by [CONTACT_427]):
 Final protocol and, if applicable, amendments .
 Sponsor -approved ICF (and any  other written materials to be provided to the participants) .
 Investigator's Brochure (or equivalent information) and amendments/addenda .
 Sponsor -approved participant recruiting materials.
 Information on compensation for study -related injuries or payment to participants for 
participation in the study , if applicable .
 Investigator's curriculum vitae or equivalent information (unless not required, as documented 
by [CONTACT_6179]/IRB) .
 Information regarding funding, name [CONTACT_8152], institutional affiliations, other potential 
conflicts of interest, and incentives for participants .
 Any other documents that the I EC/IRB requests to fulfill its obligation .
This study will be undertaken only after the IEC/IRB has given full approval of the final protocol, 
amendments (if any, excluding the ones that are purely  administrative, with no consequences for 
partici pants, data or study  conduct, unless required locall y), the ICF, applicable recruiting 
materials, and participant compensation programs, and the sponsor has received a copy of this 
approval. This approval letter must be dated and must clearly  identify the IEC/IRB and the 
documents being approved.
Approval for the collection of optional samples for research and for the corresponding ICF must 
be obtained from the IEC/IRB. Approval for the protocol can be obtained independent of this 
optional research componen t.
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
 Protocol amendments (excluding the ones that are purely  administrative, with no 
consequences for participants, data or stud y conduct) .
 Revision(s) to I CF and any  other written materials to be provided to participants.
 If applicable, new or revised participant recruiting materials approved by  [CONTACT_456].
 Revisions to compensation for study -related injuries or payment to participants for 
participation in the study , if applicable .
 New edition(s) of the Investigator's Brochure and amendments/addenda .
 Summaries of the status of the study at intervals stipulated in guidelines of the IEC/I RB(at 
least annuall y).
 Reports of adverse events that are serious, unlisted/unexpected, and associated with the stud y 
intervention .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 71
Approved , Date: [ADDRESS_493766] 2020 New information that may adversel y affect the safety of the participants or the conduct of the 
study .
 Deviations from or chan ges to the protocol to eliminate immediate hazards to the participants.
 Report of deaths of participants under the investigator's care .
 Notification if a new investigator is responsible for the study  at the site .
 Development Safet y Update Report and Line Listings, where applicable .
 Any other requirements of the IEC/I RB.
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for participants, data or study  conduct) , the amendment and applicable ICF revisions 
must be submitted promptly to the IEC/IRB for review and approval before implementation of the 
change(s).
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where required.
At the end of the study , the investigator (or sponsor where required) will notify the IEC/I RB about 
the study  completion (if applicable, the notification will be submitted through the head of 
investigational institution)
FINANCIAL DISCLOSURE
Where appropriate, investigators and subinvestigators will provide the sponsor with sufficient, 
accurate financial information in accordance with local regulations to allow the sponsor to submit 
complete and accurate financial certification or disclosure statements to the appropriate regulatory 
authorities. Investigators are responsible for providing information on financial interests during 
the course of the study  and for 1 y ear after completion of the study .
Refer to Required Prestudy  Documentation (above) and contracts for details on financial 
disclosure.
INFORMED CONSENT PROCESS
Each participant must give written consent according to local requirements after the nature of the 
study  has been fully  explained. The ICF(s) must be signed before performance of any study -related 
activity . The ICF(s) that is/are used must be approved by [CONTACT_393405] g 
IEC/IRB and be in a language that the participant can read and understand. The informed consent 
should be in accordance with principles that originated in the Declaration of Helsinki, current IC H 
and GCP guidelines, applicable regulatory  requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential participants the aims, methods, reasonably anticipa ted benefits, 
and potential hazards of the study ,and any discomfort participation in the study  may entail. 
Participants will be informed that their participation is voluntary  and that they may withdraw 
consent to participate at any time. They  will be info rmed that choosing not to participate will not 
affect the care the participant will receive .Finally , they will be told that the investigator will 
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 72
Approved , Date: [ADDRESS_493767] 2020maintain a participant identification register for the purposes of long -term follow up if needed and 
that the ir records may be accessed by [CONTACT_393406], to the extent permitted by [CONTACT_6983](s) or 
regulations. By [CONTACT_130432]. It also denotes that the 
participant agrees to allow his or her study  physician to recontact [CONTACT_393407] y evaluations , if needed.
The participant will be given sufficient time to rea d the I CF and the opportunity  to ask questions. 
After this explanation and before entry  into the study , consent should be appropriatel y recorded by 
[CONTACT_67824]'s personally dated signature. After having obtained the consent, a cop y of 
the ICF must be given to the participant.
Participants who are rescreened are required to sign a new ICF, will be assigned a new participant 
number, and then restart a new screening phase.
DATA PROTECTION
The collection and processing of personal data from partici pants enrolled in this study will be 
limited to those data that are necessary  to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized disclosures 
or access, accidental or unlawful destruction, or accidental loss or alteration must be put in place. 
Sponsor personnel whose responsibilities require access to personal data agree to keep the identit y 
of participants confidential.
The informed consent obtained from the participant includes explicit consent for the processing of 
personal data and for the investiga tor/institution to allow direct access to his or her original medical 
records (source data/documents) for study -related monitoring, audit, IEC/IRB review, and 
regulatory  inspection. This consent also addresses the transfer of the data to other entities andto 
other countries.
The participant has the right to request through the investigator access to his or her personal data 
and the right to request rectification of an y dat a that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
Pharmacokinetic , immunogenicity  and biomarker research isnot conducted under standards 
appropriate for the return of data to participants. In addition, the sponsor cannot make decisions as 
to the significance of any findings resulting from this research. Therefore, such research data will 
not be returned to participants or investigators, unless required by [CONTACT_67827]. Privacy
and confidentiality of data generated in the future on stored samples will be protected b y the same 
standards applicable to all other clinical data.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 73
Approved , Date: [ADDRESS_493768] 2020LONG -TERM RETENTION OF SAM PLES FOR ADDITIONAL FUTURE RESEARCH
Samples collected in this study  may be stored for up to 15 y ears (or according to local regulations) 
for additional research. Samples will only be used to understand ustekinumab , to understand 
Crohn’s disease , to under stand differential intervention responders, and to develop tests/assays 
related to ustekinumab andCrohn’s disease . The research may  begin at any  time during the study  
or the post -study  storage period.
Stored samples will be coded throughout the sample s torage and analy sis process and will not be 
labeled with personal identifiers. Participants may withdraw their consent for their samples to be 
stored for research (refer to Section 7.2.1 ).
PUBLICATION POLICY /DISSEMINATION OF CLINICAL STUDY DATA
All information, including but not limited to information regarding ustekinumab or the sponsor's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by [CONTACT_43787], and any data, including exploratory  research data, generated as a result of
this study , areconsidered confidential and remain the sole propert y of the sponsor. The investigator 
agrees to maintain this information in confidence , touse this information only  to accomplish this 
study ,andwill not use it for other purposes without the sponsor's prior written consent.
The investigator understands that the information developed in the study will be used by [CONTACT_393408]. To permit the information derived 
from clinical studies to be used, the investigator is obligated to provide the sponsor with all data 
obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by [CONTACT_66896]. Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator [INVESTIGATOR_393372] . Results of biomarker 
analysesperformed after the Clinical Study  Report has been issued will be reported in a separate 
report and will not require a revision of the Cli nical Study  Report.
Study  participant identifiers will not be used in public ation of results. Any work created in 
connection with performance of the study  and contained in the data that can benefit from copyright 
protection (except an y publication by [CONTACT_40999]) shall be the property 
of the sponsor as a uthor and owner of copy right in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors (ICMJE) guidelines, the sponsor shall have the right to publish such primary (multicenter) 
data and information without approval from the investigator. The investigator has the right to 
publish study  site-specific data after the primary  data are published. If an investigator wishes to 
publish information from the study ,a copy of the manuscript must be provided to the sponsor for 
review at least 60 days before submission for publication or presentation. Expedited reviews will 
be arranged for abstracts, poster presentations, or other materials. If requested by [CONTACT_393409] (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 74
Approved , Date: [ADDRESS_493769] made a significant contribution to the conception or design 
of the work; or the acquisition, analy sis, or interpretation of t he data for the work; and drafted the 
work or revised it critically  for important intellectual content; and given final approval of the 
version to be published; and agreed to be accountable for all aspects of the work in ensuring that 
questions related to the accuracy or integrit y of any part of the work are appropriatel y investigated 
and resolved.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as require d 
by [CONTACT_2371].
DATA QUALITY ASSURANCE
Data Quality Assurance/Quality Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -site personnel before the study , and periodic monitoring visits by [CONTACT_456], and direct 
transmission of clinical laboratory  data from a central laboratory  into the sponsor's data base. 
Written instructions will be provided for col lection, handling, storage, and shipment of samples.
Guidelines for CRF completion will be provided and reviewed with study -site personnel before 
the start of the stud y.
The sponsor will review CRF for accuracy  and completeness during on- site monitoring vi sits and 
after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designee, as appropriate. After upload of the data into the study database they  will be verified for 
accuracy  and consistency with the data sources.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 75
Approved , Date: [ADDRESS_493770].
The study  data will be transcribed by [CONTACT_3449]-sitepersonnel from the source documents onto the
electronic CRF, if applicable. Study -specific data will be transmitted in a secure manner to the 
sponsor.
Worksheets may be used for the capture of some data to facilitate completion of the CRF. Any 
such worksh eets will become part of the participant's source documents. Data must be entered into 
CRF in English. The CRF must be completed as soon as possible after a participant visit and the 
forms should be available for review at the next scheduled monitoring vis it.
All participative measurements will be completed by [CONTACT_66831].
If necessary , queries will be generated in the eDC tool. If corrections to a CRF are needed after 
the initial entry  into the CRF , this can be done in either of the following way s:
Investigator and study -site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  [CONTACT_66832]).
Sponsor or sponsor delegate ca n generate a query for resolution b y the investigator and stud y-
site personnel.
SOURCE DOCUMENTS
At a minimum, source documents consistent in the type and level of detail with that commonl y 
recorded at the study  site as a basis for standard medical care mu st be available for the following: 
participant identification, eligibility , and study  identification; study  discussion and date of signed 
informed consent; dates of visits; results of safety  and efficacy  parameters as required by [CONTACT_12695]; record of all adverse events and follow -up of adverse events; concomitant medication; 
intervention receipt/dispensing/return records; study  intervention administration information ; and 
date of study  completion and reason for earl y discontinuation of study  intervention or withdrawal 
from the study , if applicable.
The author of an entry  in the source documents should be identifiable.
Specific details required as source data for the study  and source data collection methods will be 
reviewed with the investigator before thestudy ,and will be described in the monitoring guidelines 
(or other equivalent document).
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 76
Approved , Date: [ADDRESS_493771] 2020The following data will be recorded directl y into the CRF and will be considered source data :
Investigator -completed scales and assessments.
PRO s.
The minimum source documentation requirements for the inclusion and exclusion criteria that 
specify  a need for documented medical history  (see Sections 5.1and 5.2) are as follows:
Referral letter from treating ph ysician.
Complete history  of medical notes at the site .
Discharge summaries .
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by [CONTACT_67833] (eg, physical 
examination, laboratory  assessment) and documented in the source documents.
An eSource system may be utilized, which contains data traditionally  maintained in a hospi[INVESTIGATOR_90761] (eg, electronic source documents) as well as the clinical 
study -specific data fields as determined by [CONTACT_760]. This data is electronically extracted for 
use by [CONTACT_456]. If eSource is utilized, references made to the CRF in the protocol include the 
eSource system, but information collected through eSource may not b e limited to that found in the 
CRF.
MONITORING
The sponsor will use a combination of monitoring techniques, central, remote, or on-site 
monitoring to monitor this study .
The sponsor will perform on-site monitoring visits as frequently  as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compare the data entered into the CRF with the source documents 
(eg,hospi[INVESTIGATOR_307]/clinic/phy sician’s office medical records). The nature and location of all source 
documents will be identified to ensure that all sources of original data required to complete the 
CRF are known to the sponso r and study -site personnel and are accessible for verification by [CONTACT_66886] -site contact. If electronic records are maintained at the study  site, the method of 
verification must be discussed with the study -site personnel.
Direct access to source documents (medical records) must be allowed for the purpose of verifying 
that the recorded data are consistent with the original source data. Findings from this review will 
be discussed with the study -site personnel. The sponsor expects that, during monitori ng visits, the 
relevant study -site personnel will be available, the source documents will be accessible, and a 
suitable environment will be provided for review of study -related documents. The monitor will 
meet with the investigator on a regular basis durin g the study to provide feedback on the study
conduct.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 77
Approved , Date: [ADDRESS_493772] for data identified by  [CONTACT_70467].
ON-SITE AUDITS
Representatives of the sponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and compan y policy . These audits will require access to all study 
records, including source documents, for inspection. Participant privacy must, however, be 
respected. The investigator and study -site personnel are responsible for being present and available 
for consultation during routinely  scheduled study -site audit visits conducted by  [CONTACT_66893].
Similar auditing procedures may also be cond ucted by [CONTACT_23865], either as part 
of a national GCP compliance program or to review the results of this study  in support of a 
regulatory submission. The investigator should immediately  notify  the sponsor if he /she has been 
contact[INVESTIGATOR_530] b ya regulatory agency  concerning an upcoming inspection.
RECORD RETENTION
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all CRF and 
all source documents that support the data collected from each participant, as well as all study  
documents as specified in I CH/GCP Section 8, Essential Documents for the Conduct of a Clinical 
Trial, and all study  documents as specified by [CONTACT_23859](s). The 
investigator/institution will take measures to prevent a ccidental or premature destruction of these 
documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing applications 
in an ICH region or until at least [ADDRESS_493773]. These documents will be retained for a longer period 
if required by [CONTACT_393410]. It is the 
responsibility  of the sponsor to inform the investigator/institution as to when these documents no 
longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keepi[INVESTIGATOR_13274], custody  must be transferred to a person who will accept 
the responsibility . The sponsor must be notified in writing of the name [CONTACT_66903]. Under no circumstance shall the investigator relocate or dispose of any study documents 
before having obtained written approval from the sponsor.
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator/institution must permit access to such reports.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 78
Approved , Date: [ADDRESS_493774] been collected 
and a stud y-site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of a study  site by [CONTACT_66892]:
Failure of the investigator to compl y with the protocol, the requirements of the IEC/IRB or 
local health authorities, the sponsor's procedures, or GCP guidelines .
Inadequate recruitment of participants by  [CONTACT_093].
Discontinuation of further study  intervention development .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 79
Approved , Date: [ADDRESS_493775] 202010.7. Appendix 7: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
ADVERSE EVENT DEFINITIONS AND CLASSIFICATIONS
Adverse Event
An adverse event is any  untoward medical occurrence in a clini cal study  participant administered 
a medicinal (investigational or non-investigational) product. An adverse event does not necessaril y 
have a causal relationship with the intervention . An adverse event can therefore be any unfavorable 
and unintended sign ( including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (investigational or non -investigational) product, whether or not related 
to that medicinal (investigational or non-investigational) product. (Definition per International 
Conference on Harmonisation [I CH])
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to ‘All 
Adverse Events ’under Section 8.3.[ADDRESS_493776] adverse event recording).
Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any  untoward medical occurrence that at an y dose:
Results in death.
Is life threatening (ie, participant was at risk of death at the time of the event -does not refer 
to an event that h ypothetically might have cause d death if it were more severe).
Requires inpatient hospi[INVESTIGATOR_1081] .
Results in persistent or signific ant disability /incapacity .
Is a congenital anomal y/birth defect .
Is a suspected transmission of an y infectious agent via a medicinal product.
Is medicall y important*
*Medical and scientific judgment should be exercised in deciding whether expedited report ing is also appropriate 
in other situations, such as important medical events that may not be immediately life threatening or result in 
death or hospi[INVESTIGATOR_393373]. These should usually be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study  intervention and the event (eg, death from ana phylaxis), the event 
must be reported as a serious and unexpected suspected adverse reaction even if it is a component 
of the study endpoint (eg, all -cause mortality ).
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 80
Approved , Date: [ADDRESS_493777] 2020Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severit y is not consistent with the applicable 
product reference safety  information. For ustekinumab , the expectedness of an adverse event will 
be determined b y whether or not it is listed in the Investigator's Brochure .
Adverse Event Associated With the Use of the Intervention
An adverse event is considered associated with the use of the intervention if the attribution is at 
least possible (ie, possible , probable, or very  likely ) based on the definitions listed below .
ATTRIBUTION DEFINITIONS
Not Related
An adverse event that is not related to the use of the intervention .
Doubtful
An adverse event for which an alternative explanation is more likely , eg,concomitant treatment (s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An adverse event that might be due to the use of the intervention . An alternative explanation, 
eg,concomitant treatment(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the intervention . The relationship in time is 
suggestive (eg,confirmed by [CONTACT_23827]). An alternative explanation is less l ikely , 
eg,concomitant treatment(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explained 
by [CONTACT_4867], eg,concomitant treatment (s), concomitant disease(s). The 
relationship in time is very suggestive (eg, it is confirmed by  [CONTACT_35719]).
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 81
Approved , Date: [ADDRESS_493778] 2020SEVERITY CRITERIA
An assessment of severity grade will be made using the following general categorical descriptors:
Mild : Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate : Sufficient discomfort is present to cause interference with normal activity .
Severe : Extreme distress, causing significant impairment of functioning or incapa citation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events not directly 
experienced b y the participant (eg,laboratory  abnormalities).
SPECIAL REPORTING SITUATIONS
Safety  events of interest on a sponsor study  intervention in an interventional study that may require 
expedited reporting or safety  evaluation include, but are not limited to:
Overdose of a sponsor study  intervention .
Suspected abuse/misuse of a sponsor study  intervention .
Accidental or occupational exposure to a sponsor study  intervention .
Any failure of expected pharmacologic action (ie, lack of effect) of a sponsor study 
intervention .
Unexpected therapeutic or clinical benefit from use of a sponsor study  intervention .
Medication error, intercepted medication error, or potential medication error involving a 
[COMPANY_012] medicinal product (with or without patient exposure to the Johnson & 
Johnson medicinal product ;eg, product name [CONTACT_2976], product label confusion, intercepted 
prescribing or dispensing errors ).
Exposure to a sponsor study  intervention from breastfeeding.
Special reporting situations should be recorded in the CRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the CRF.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 82
Approved , Date: [ADDRESS_493779] be recorded using medical terminology  in the source d ocument and the CRF. 
Whenever possible, diagnoses should be given when signs and symptoms are due to a common 
etiology  (eg, cough, runny  nose, sneezing, sore throat, and head congestion should be reported as 
‘upper respi[INVESTIGATOR_23739] ’). Investigators must record in the CRF their opi[INVESTIGATOR_23740] . All measures required for adverse event 
management must be recorded in the source document and reported according to sponsor 
instructions.
For all studies with an outpatient phase, including open -label studies, the participant must be 
provided with a ‘wallet (study )card’and instructed to carr y this card with them for the duration of 
the study  indicating the following:
Study  number .
Statement, in the local language(s), that the participant is participating in a clinical study .
Investigator's name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828].
Local sponsor's name [INVESTIGATOR_1238] [ADDRESS_493780] telephone number (for medical staf f onl y).
Site number .
Participant number .
Any other information that is required to do an emergency  breaking of the blind.
Serious Adverse Events
The cause of death of a participant in a study within [ADDRESS_493781] not resolved 
upon discontinuation of the participant's participation in the study , must be followed until any of 
the following occurs:
The event resolves.
The event stabilizes .
The event returns to baseline, if a baseline value/status is available .
The event can be attributed to agents other than the study  intervention or to factors unrelated 
to study  conduct .
It becomes unlikely  that any additional information can be obtained (participant or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration of 
due diligence with follow -up efforts) .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 83
Approved , Date: [ADDRESS_493782] will be reported as a serious 
adverse event. An y event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) that occurs 
during the course of a participant's participation in a study must be reported as a serious adverse 
event , except hospi[INVESTIGATOR_23741]:
Hospi[INVESTIGATOR_23742] (eg, social reasons such 
as pending placement in long- term care facility ).
Surgery  or procedure planned before entry  into the study  (must be documented in the CRF)
Note: Hospi[INVESTIGATOR_23743], and where the 
underly ing condition for which the hospi[INVESTIGATOR_23744], will not be 
considered serious adverse events. Any adverse event that results in a prolongation of the 
originall y planned hospi[INVESTIGATOR_23745] a new serious adverse event.
For convenience the investigator may choose to hospi[INVESTIGATOR_90764].
CONTACT[CONTACT_70476] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23831] y issues or questions regarding the study  are listed in the Contact [CONTACT_23832](s), which will be provided as a separate document.
PRODUCT QUALITY COMPLAINT HANDLING
A product qualit y complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, or packaging, ie, anydissatisfaction relative to the identity , quality , 
durability , or reliability  of a product, including its labeling or package integrity . A PQC may  have 
an impact on the safet y and ef ficacy  of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of participants, 
investigators, and the sponsor , and are mandated by [CONTACT_23824]. The sponsor 
has established procedures in conformity  with regulatory  requirements worldwi de to ensure 
appropriate reporting of PQC information; all studies conducted by [CONTACT_90826].
Procedures
All initial PQCs must be reported to the sponsor by  [CONTACT_1758] -site personnel within [ADDRESS_493783] report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to ‘Serious 
Adverse Even ts’under Section 8.3.1 ). A sample of the suspected product should be maintained for 
further investigation if requested by  [CONTACT_456].
Contact[CONTACT_23834] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23835](s), which will be 
provided as a separate document.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 84
Approved , Date: [ADDRESS_493784] 202010.8. Appendix 8: Contraceptive and Barrier Guidance and Collection of 
Pregnancy  Information
Participants must follow contraceptive measures as outlined in Section 5.1. Pregnancy  information 
will be collected and reported as noted in Section 8.3.5 .
Definitions
Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanentl y sterile (see below).
Woman Not of Childbearing Potential
Premenarchal
A premenarchal state is one in which mena rche has not y et occurred.
Postmenopausal
A postmenopausal state is defined as no menses for 12 months without an alternative medical 
cause. A high follicle stimulating hormone (FSH)level (>40 IU/L or mIU/mL) in the 
postmenopausal range may be used to confirm a postmenopausal state in women not using 
hormonal contraception or hormonal replacement therapy  (HRT), however in the absence of 
12months of amenorrhea, a single FSH measurement is insufficient.
If there is a question about menopausal status in women on HRT, the woman will be required 
to use one of the non -estrogen -containing hormonal highl y effective contraceptive methods if 
she wishes to continue HRT during the stud y.
Permanently sterile
Permanent sterilization methods include hysterectomy , bilateral salpi[INVESTIGATOR_1656] , bilateral tubal 
occlusion/ligation procedures, and bilateral oophorectomy .
NOTE : If the childbearing potential changes after start of the study  (eg, a premenarchal woman 
experiences menarche) or the risk of pregnancy  changes (eg, a woman who is not heterosexuall y 
active becomes active), a woman must begin a highl y effective method of contraception, as 
described throughout the inclusion criteria.
If reproductive status is questionable, additional evaluation should be considered.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 85
Approved , Date: [ADDRESS_493785] 2020Examp les of Contraceptives
Contraceptive use by [CONTACT_393411].
Examples of highly  effective contraceptives (ie, failure rate ≤1% per year when used consistently  
and correctl y, which may differ from t ypi[INVESTIGATOR_393374] ) allowed during the stud y include:
USER INDEPENDENT :
Implantable progestogen -only hormone contraception associated with inhibition of ovulationa
Intrauterine device
Intrauterin e hormone -releasing system
Bilateral tubal occlusion
Vasectomized partner (considered a highly effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the absence of sperm 
has been confirmed. If not, additional highly effective method of contraception should be used. 
Spermatogenesis cycle is approximately 74days.)
USER DEPENDENT:
Combined (estrogen- and progestogen- containing) hormonal contraception associated with 
inhibition of ovulationa
oral
intravaginal
transdermal
injectable
Progestogen -only hormone contraception associated with inhibition of ovulationa
oral
injectable
Sexua l abstinence (considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study intervention. 
The reliability of sexual abstinence needs to be evaluated in relation t o the duration of the study 
and the preferred and usual lifestyle of the participant .)
a.Hormonal contraception may be susceptible to interaction with the study intervention, which may 
reduce the efficacy of the contraceptive method. In addition, conside r if the hormonal 
contraception may interact with the study intervention.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 86
Approved , Date: [ADDRESS_493786] 2020Examples of contraceptives that are not considered to be highl y effective (ie, failure rate >1% per 
year) and that are not allowed during the study  include:
Progestogen -only oral hormonal contraception where inhibition of ovulation is not the primary 
mode of action
Male or female condom with or without spermicidea
Cap, diaphragm, or sponge with spermicide
A combination of male condom with either cap, diaphragm, or sponge with sp ermicide (double -
barrier methods)a
Periodic abstinence (calendar, symptothermal, post -ovulation methods)
Withdrawal (coitus -interruptus)
Spermicides alone
Lactational amenorrhea method (LAM)
a.Male condom and female condom should not be used together (due to risk of failure with friction )
Pregnancy During the Study
A female participant who becomes pregnant during the study  must discontinue further study 
intervention. Follow -up information regarding the outcome of the pregnancy  and any postnatal 
seque lae in the infant will be required.
Because the effect of the study intervention on sperm is unknown, pregnancies in partners of male 
participants included in the study  will be reported. A male study  participant is not required to 
discontinue study  interve ntion if their partner becomes pregnant during the study .
Pregnancy Testing
A woman of childbearing potential must have a negative serum pregnancy test at screening and a 
negative urine pregnancy  test at all dosing visits prior to administration of study  intervention.
Additional serum or urine pregnancy  tests may be performed, as determined necessary  by [CONTACT_41011], to establish the absence of pregnancy  at any time 
during the participation in the study .
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 87
Approved , Date: [ADDRESS_493787] 202010.9. Appendix 9: Protocol A mendment History
This is the fourth global amendment. The summary of changes table for the current amendment is 
located directl y before the Table of Contents (TOC) . The summary  of changes table sfor the 
previous amendment sare presented below:
Amendment 3, 19 May 2020
Overall Rationale for the Amendment: To allow subcutaneous injections of study intervention at Week 8 
and Week 16 to be self -administered outside a study site, in cases where a site visit is not possible.
Section Number
and Nam e Description of Changes and Brief Rationale
1.1Synopsis; 1,3 Schedule of 
Activities; 6.1 Study 
Intervention; 6.2.2 Drug 
Accountability; 6.4 Study 
Intervention Compliance; Description of Change:
Added text to allow  subcutaneous in jections of study intervention at Week [ADDRESS_493788] received instructions for storage and 
handling of study materials.
Rationale:   To provide flexibility of dose administration in exceptional cases 
where a study site visit is not possible.
5.2. Exclusion Criteria Description of Change:
Added exclusion criterion 27, to document exclusion of patients with confirmed 
or suspected SARS -CoV -[ADDRESS_493789] with a 
person w ith confirmed or suspected SARS -CoV -2 infection wit hin 6 weeks 
before baseline and to provide COVID- 19-related guidance on study 
participation and exclusion.
Rationale:   To exclude patients with confirmed or potential SARS -CoV- 2 
infection.
8.2 Safety Assessments Description of Change:   Added instruction s on adverse event reporting for 
participants who self-administer SC study intervention .
Rationale: To provide safety reporting guidance outside the study site.
Appendix 7: Adverse Events: 
Definitions andProcedures 
for Recording, Evaluating , 
Follow -up,and ReportingDescription of Change:   Clarified the special reporting situation ‘Medication 
error’ to also include intercepted and potential medication errors for a Johnson 
& Johnson medicinal product.
Rationale: To be consistent with safety reporting r equirements.
Investigator Agreement Page Description of Change:   Changed the name [CONTACT_19618]’s Responsible 
Medical Officer.
Rationale:   To reflect the ne w assignment of the responsible physician for this 
study.
Amendment 2, 8 April 2020
Overall Rationale for the Amendment: To allow for self-administration of subcutaneous study 
intervention at Weeks 8 and 16 outside a study site (eg, at home), in cases where a study site visit is not 
possible under restrictions and limitations during the COVID -[ADDRESS_493790] 
During the COVID- 19 
PandemicDescription of Change:   Added appendix as guidance on changes to study 
conduct and assessments due to restrictions and limitations during the 
COVID -19 pandemic.
Rationale: To provide guidance on study conduct and assessments during the 
COVID -19 pandemic.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 88
Approved , Date: [ADDRESS_493791] 2020Amendment 1, 19 July 2019
Overall Rationale for the Amendment: To include information regarding the planned primary endpoin t 
database lock at Week 16 and the final database lock. Other clarifications and changes were made to address 
investigator and site questions surrounding operational elements of the study.
Section Number
and Nam e Description of Change s and Brief Rationale
4.2 Scientific Rationale for 
Study DesignDescription of Change:   Added information regarding the planned primary 
endpoint database lock at Week 16 (w hen all participants have completed 
Week [ADDRESS_493792] terminated study participation prior to Week 16) and the final 
database lock (when all participants have completed Wee k36 or have 
terminated study participation prior to Week 36).
Rationale:   Clarify the planned database locks, the first for pe riodic 
summarization of the primary endpoint and selected data at Week 16 and the 
second for the final analysis.
1.3 Schedule of Activities; 
5.1Inclusion CriteriaDescription of Change:   Increased the time window during which a prior 
radiograph taken within normal clinical practice may be used for tuberculosis 
and infection screening from 3 months to 6 months before Week 0.
Rationale:   Eligible patients would have been on ustekinumab therapy for at 
least 4 months at screening. The initial 3-month window  before Week 0 within 
which a prior radiograph taken within normal clinical practice may be used for 
screening was not reflective of the study design ; all patients eligible for the 
study will have received ustekinumab treatment for at least [ADDRESS_493793] -of-care for 
tuberculosis screening of patients on ustekinumab therapy and potentially 
reduce radiation exposure, this w indow  was increased to 6 months before 
Week 0.
5.1 Inclusion Criteria
(Inclusion Criterion 6)Descrip tion of Change:   Changed the window for a negative TB test result 
before the first study intervention from [ADDRESS_493794] r adiograph.
Rationale:   To align with the [ADDRESS_493795] -of-care practices at study sites.
1.3 Schedule of Activities. Description of Change:   Addressed the follow ing corrections in the Schedule 
of Activities for consistency with existing protocol text:
Stool sample for fecal calprotectin added at screening.
Preplanned surgery/procedures removed after baseline.
Clarified measurement of vital signs at time of SC injections.
Moved collection of height from baseline to screening.
Remo ved collection of weight from screening measures (collected at 
baseline)
Clarified collection of IBDQ at the early termination visit for patients who 
discontinued before Week 16.
Rationale: To clarify the Schedule of Activities , to align with protocol text and 
address questions from investigators .
1.1 Synopsis; 3. Objectives 
and EndpointsDescription of Change:   Removed vital signs from listed endpoints.
Rationale:   Vital signs will be collected and reported as safety evaluations or 
adverse events, butchanges in vital signs will not be assessed as study 
endpoints.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 89
Approved , Date: [ADDRESS_493796] 2020Section Number
and Nam e Description of Change s and Brief Rationale
1.1 Synopsis; 1.2Schema; 
1.3Schedule of Activities 
(footnote b); 4.1. Overall 
Design ; 7.2 Participant 
Discontinuation/Withdrawal 
From  the Study; 8. Study 
Assessments and Procedures; Description of Change:   Clarified timing of safety follow up as 20 weeks after 
a participant’s last study intervention administration (ie, Week 36 for 
participants who complete the final study intervention visit at Week 16).
Rationale:   Allow  early follow -up for participants who discontinue before 
Week 16.
1.3 Schedule of Activities; 
8.5 Pharmacokinetic and 
ImmunogenicityDescription of Change:   Clarified collection of pharmacokinetic and 
immunogenicity blood samples in relation to stu dy intervention.
Rationale:   Clarification of timing of blood sampling.
1.1 Synopsis; 4.1. Overall 
Design; 5.1 Inclusion CriteriaDescription of Change:   Clarified definition of secondary loss of response 
based on endoscopy as within 3months before or at baseline and removed less 
specific wording that this is to be during the current disease flare .
Rationale:   To provide more specific definition of secondary loss of response.
1.1 Synopsis; 6.1. Study 
Interventions AdministeredDescription of Change:   Added clarification that either the IV infusion or SC 
injection may be administered first at Week 0 and provided guidance on 
minimum time windows between study interventions at Week 0.
Rationale:   Clarification of initial study in tervention.
4.4 End of Study Definition Description of Change: Corrected the definition for completion of the primary 
efficacy period (from Week 24 to Week 16).
Rationale:   Correction of primary efficacy period.
1.3 Schedule of Activities; 
8.1.5 Inflam matory Bow el 
Disease QuestionnaireDescription of Change: Indicated that participants who do not remain in the 
study until Week 16 or do not perform the IBDQ at Week 16 should complete 
theIBDQ at the early termination visit.
Rationale:   Clarification of early  termination assessment of IBDQ.
8.8Biomarkers Description of Change: Added information on serum /whole- blood -based 
biomarkers. 
Rationale:   Additional details and clarification of biomarker assessments.
10.11 Appendix 11: CDAI 
Standard Weight TableDescription of Change: Added a standard w eight table for CDAI .
Rationale:   Provided additional information for CDAI determination.
Throughout the protocol Description of Change: Minor grammatical /spelling changes and clarifications 
made.
Rationale: Minor changes only, therefore are not summarized.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 90
Approved , Date: [ADDRESS_493797] 202010.10. Appendix 10: Sample Crohn’s Disease A ctivity Index

STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 93
Approved , Date: [ADDRESS_493798] 202010.12. Appendix 12: Sample Inflammatory  Bowel Disease Questionnaire
Copyright © 1989 McMaster University , Hamilton, Ontario, Canada
The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by  [INVESTIGATOR_124]. Jan Irvine et al, is the copy right of 
McMaster University  (Cop yright ©1989, McMaster University ). The IBDQ has been provided under license 
from McMaster University and must not be copi[INVESTIGATOR_530], dis tributed or used in any  way  without the prior written 
consent of McMaster University . Contact [CONTACT_393412] , email: 
[EMAIL_7550] for licensing details.
Updated from: IBDQ -[LOCATION_008] -English -Version of 09 May 08 -Mapi [INVESTIGATOR_72822].
ID4529/IBDQ_AU2 0_eng -GB.doc
IBDQ (enGB) 03JUN2016 FINAL –ICON Language Services
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 94
Approved , Date: [ADDRESS_493799] 2020INSTRUCTIONS FOR SELF -ADMINISTERED INFLAMMATORY BOW EL 
DISEASE QUESTIONNAIRE (IBDQ)
This questionnaire is designed to measure the effects of your inflammatory bowel 
disease on your daily function and quality of life. You will be asked about 
symptoms you have been having as a result of your bowel disease ,the way you 
have been feeling in general ,and how your mood has been.
There are [ADDRESS_493800] 2 w eeks?
[ADDRESS_493801] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY A NY OF THE TIME
7 NONE OF THE TIME
If you are having trouble understanding a question, STOP for a moment!
Think about what the question means to you. How is it affected by [CONTACT_393413]? Then answer the question as best you can. You will have the chance to 
ask the research assistant questions after completing the questionnaire. This 
takes only a few minutes to complete.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 95
Approved , Date: [ADDRESS_493802] 2020QUA LITY OF LIFE IN INFLA MMA TORY BOWEL DISEA SE QUESTIONNA IRE (IBDQ)
This questionnaire is designed to find out how you have been feeling during the last 
2weeks. You will be asked about symptoms you have been having as a result of your  
inflammatory  bowel disease, the way you have been feeling in general, and how your mood 
has been.
1. How f requent have your bowel movements been during the last 2weeks? Please indicate 
how f requent your bowel movements have b een during the last two weeks by [CONTACT_21173][INVESTIGATOR_393375]
[ADDRESS_493803] 2 weeks? Please indicate how of ten the feeling of fatigue or tiredness has 
been a problem for you during the last [ADDRESS_493804] you felt frustrated, impatient or restless? Please 
choose an option from
[ADDRESS_493805] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 96
Approved , Date: [ADDRESS_493806] you been unable to attend school or do your work 
because of your bowel problem? Please choose an option from
[ADDRESS_493807] your bowel movements been loose?
Please choose an option from
[ADDRESS_493808] 2 weeks? Please choose an option from
[ADDRESS_493809] surgery because of your bowel problem? Please choose an option from
[ADDRESS_493810] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 97
Approved , Date: [ADDRESS_493811] you had to delay or cancel a social engagement 
because of your bowel problem? Please choose an option from
[ADDRESS_493812] you been troubled by [CONTACT_393414]?  
Please choose an option from
[ADDRESS_493813] you felt generally unwell? Please choose an option 
from
[ADDRESS_493814] you been troubled because of fear of not finding 
a toilet? Please choose an option from
[ADDRESS_493815] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 98
Approved , Date: [ADDRESS_493816] 2 weeks? Please choose 
an option from
1 A GREAT DEAL OF DIFFICULTY; ACTIVITIES MADE IMPOSSIBLE
2 A LOT OF DIFFICULTY
3 A FAIR BIT OF DIFFICULTY
4 SOME DIFFICULTY
5 A LITTLE DIFFICULTY
6 HARDLY ANY DIFFICULTY
7 NO DIFFICULTY; THE BOW EL PROBLEMS DID NOT LIMIT SPORTS OR LEISURE 
ACTIVITIES
13. How often during the last [ADDRESS_493817] youbeen troubled by [CONTACT_393415]? Please 
choose an option from
[ADDRESS_493818] you had pr oblems getting a good night’s sleep or 
been troubled by [CONTACT_212964]? Please choose a n option from
[ADDRESS_493819] you felt depressed or discouraged? Please choose 
an option from
[ADDRESS_493820] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 99
Approved , Date: [ADDRESS_493821] you had toavoid attending events where there 
was no toilet close at hand? Please choose an option from
[ADDRESS_493822] you had with passing large 
amounts of wind? Please choose an option from
[ADDRESS_493823] you had maintaini ng or getting 
tothe weight you would like to be at? Please choose an option from
[ADDRESS_493824] you 
felt wo rried or anxious? Please choose an option from
[ADDRESS_493825] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 100
Approved , Date: [ADDRESS_493826] you been troubled by a feeling of 
abdominal bloating? Please choose an option f rom
[ADDRESS_493827] you felt relaxed and free of tensi on? Please 
choose an option from
[ADDRESS_493828] you had a problem with rectal bleeding 
with your bowel movements? Please choose an option from
[ADDRESS_493829] you felt embarrassed as a result of 
your bowel problem? Please choose an option from
[ADDRESS_493830] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 101
Approved , Date: [ADDRESS_493831] you been troubled by a feeling of 
having to go to the toilet even though your bowels were empty? Please choose an option 
from
[ADDRESS_493832] you felt tearful or upset? Please choose 
an option from
[ADDRESS_493833] you been troubled by [CONTACT_393416]? Please choose an option from
[ADDRESS_493834] you felt angry as a result of your bowel 
problem? Please choose an option from
[ADDRESS_493835] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 102
Approved , Date: [ADDRESS_493836] 2 weeks? 
Please choose an option from
[ADDRESS_493837] you been troubled by [CONTACT_393417]? Please choose an option from
[ADDRESS_493838] you felt irritable? Please choose an 
option from
[ADDRESS_493839] you felta lack of understanding from others? 
Please choose an option from
[ADDRESS_493840] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 103
Approved , Date: [ADDRESS_493841] 2 
week s? Please choose one of the following options from
[ADDRESS_493842] BEEN MORE HAPPY OR PLEASED
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 104
Approved , Date: [ADDRESS_493843] 202010.13. Appendix 13: Guidance on Study  Conduct during the COVID -19 Pandemic
BACKGROUND
It is recognized that the Coronavirus Disease 2019 (COVID -19) pandemic may  have an impact on 
the conduct of this clinical study  due to, for example, self-isolation/quarantine by [CONTACT_393418]/orstudy -site personnel; travel restrictions and limited access to public places, including 
hospi[INVESTIGATOR_600]; and study  site personnel being reassigned to critic al tasks.
In alignment with recent health authority  guidance, the sponsor is providing options for study -
related participant management in the event of disruption to the conduct of the study . This guidance 
does not supersede any  local or government guideli nes or requirements or the clinical judgement 
of the investigator to protect the health and well -being of participants and site staff. If at any  time 
a participant’s safet y is considered to be at unacceptable risk, study intervention will be 
discontinued, and study  follow -up will be conducted.
Scheduled visits that cannot be conducted in person at the study  site will be performed to the extent 
possible remotel y, virtually , or will be delay ed until such time that on -site visits can be resumed. 
At each contac t, participants will be interviewed to collect safety  data. Key efficacy  endpoint 
assessments should be performed if required and as feasible. Participants will also be questioned 
regarding general health status to fulfill any  physical examination requirem ent.
Every  effort should be made to adhere to protocol -specified assessments for participants on study 
intervention, including follow up. Modifications to protocol -required assessments may be 
permitted after consultation between the participant and investi gator, and with the agreement of 
the sponsor (see below) .
The sponsor will continue to monitor the conduct and progress of the clinical study  and any 
changes will be communicated to the sites and health authorities according to local guidance.
If a partici pant has tested positive for COVID 19, the investigator should contact [CONTACT_456]’s 
responsible medical officer or designee to discuss plans for study  intervention and follow -up.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 105
Approved , Date: [ADDRESS_493844] 2020GUIDANCE SPECIFIC TO THIS PROTOCOL
Study Population
Exclusion Criteria (Protocol Section 5.2)
A potential participant with the following features will be excluded from participating in the study .
27. Criterion added per Amendment 2:
During the 6weeks prior to baseline, have had ANY of (a) confirmed SARS -CoV -2 
(COVID -19) infecti on (test positive), OR (b) suspected SARS -CoV -2 infection (clinical 
features without documented test results), OR (c) close contact [CONTACT_4490] a person with known 
or suspected SARS -CoV -2 infection.
Exception: may be included with a documented negative result fora validated 
SARS -CoV -[ADDRESS_493845]
obtained at least 2weeks after conditions (a), (b), or (c) above (timed from 
resolution of key  clinical features if present, eg, fever, cough, d yspnea)
AND
with absence of ALL conditions (a), (b) and (c) above during the period between 
the negative test result and the baseline stud y visit.
Notes on COVID- related Exclusion
If a patient is excluded due to recent COVID -19-related features, the reason for screen failure 
should be documented in the case report form (CRF) under the exclusion criterion of having 
a condition for which participation would not be in the participant’s interest or could confound 
study  assessments.
The field of COVI D-related testing (for presence of, and immunity  to, the SARS -CoV -2 virus) 
is rapi[INVESTIGATOR_393364]. Additional testing may be performed as part of screening and/or during 
the study  if deemed necessary  by [CONTACT_393419], 
guidance from authorities, or standards of care.
Precautions
For those patients who may carry a higher risk for severe COVID -19 illness (eg,patients aged over 
65years), follow the guidance from local health authorities when considering the potential benefits 
and risks of enrolling patients into the study  and during study  participation.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 106
Approved , Date: [ADDRESS_493846] 2020Study Interventions and Assessments
Certain protocol -mandated visits to the study  site may not be possible during the COVID -19 
outbreak; therefore, temporary  measures may be implemented if considered appropriate by [CONTACT_393420] y. Certain 
measures, such as those listed below, may be necessary  and should be instituted in accordance 
with applicable (including local) laws, regulations, guidelines, and procedures.
Administration of Study Intervention
In cases where a site visit is not possible under restrictions and limitations due to the COVID -19 
pandemic, participants may self-administer subcutaneous (SC) injections of study  intervention 
outside a study  site (eg, at home) at Weeks 8 and 16. Those participants will receive instructions 
on compliance, storage, disposal of used syringes, handling of unused study material, and adverse 
event reporting. The specific protocol changes are documented below:
Study Interven tions Administered (Protocol Section 6.1)
Subcutaneous injections at Week [ADDRESS_493847] may self-administer SC study 
intervention (in compliance with the SmPC or local label ) at the times instructed by [CONTACT_1275].
Study -site personnel will instruct participants on how to store study  intervention for at- home use. 
For each administration of study  intervention , the time and date of injection, whether study  
intervention was self -administered, and if so, wh ether SC administration was complete (based on 
the returned s yringe [s])will be recorded in the CRF.
Drug Accountability and Compliance (Protocol Sections 6.2.2 and 6.4)
Study  intervention at Week [ADDRESS_493848] the time and date of study intervention administrations in the diary. Stud y 
site personnel will utilize participant’s diaries to ensure compliance and record at-home study  
intervention administrations in the eCRF.
Any participant who will be self -administering study  intervention at home at Weeks 8 and 16 will 
receive detailed instructions on storage ofstudy intervention, disposal of used syringes, and 
handling of unused study material.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 107
Approved , Date: [ADDRESS_493849] 2020Notes on Shipment of Study Inte rvention to Participants
If it is necessary  to ship the study  intervention directly  to study  participants, shipment by [CONTACT_393421] D-19 pandemic. Shipment should be 
made in a manner that allows tracking of both transport and delivery . The participant should 
acknowledge receipt of the shipment to the site (eg, b y returning a dated and signed receipt form).
In case adequate shipment by [CONTACT_393422] (for example, owing to capacit y 
limitations, logistics, or special transport conditions for the study intervention), direct transport by 
[CONTACT_393423], provided that the sponsor appoints a 
suitably  qualified service provider as trustee. The spons or must contractually  oblige this service 
provider to maintain the pseudony mization and, if necessary , blinding of study  participants to the 
sponsor using appropriate measures. Both the transport and handover conditions for study  
intervention should be par t of the contractual arrangements, so that pharmaceutical drug safet y of 
study  intervention as well as protection of the privacy  and personal data of participants are 
adequatel y safeguarded. The study  intervention must be delivered directl y to the particip ant or a 
person authorized by  [CONTACT_2299], and must not be given to neighbors or deposited at a storage 
location. Written confirmation of dose and dose regimens by [CONTACT_393424].
The personnel of the service provider in charge of the transport should be trained and instructed 
accordingl y. As personal data are transferred to the service provider, this requires a contract of 
assignment with the sponsor or legal representative.
For direct shipment of study  intervention to participants, written instructions on storage and return 
of used and unused study intervention should be provided to participants. When shipped by  [CONTACT_393425], the receipt, consumption and return of study intervention must be documented in a for m that 
allows the study  site to meet its documentation requirements (ie, drug accountability ), as defined 
in ICH GCP 4.6.3.
Study Assessments and Analyses
Safety Assessments (Protocol Section 8.2)
In cases of self-administration of SC study  intervention athome, participants are requested to 
contact [CONTACT_393426].
Clinical laboratory  safety  monitoring may be performed at a certified local laboratory  identified 
by [CONTACT_393427] ;for selected measures (eg, urine pregnancy), 
home testing may  be employ ed.
Missed Assessments
Missed assessments/visits will be captured in the clinical trial management system for protocol 
deviations. Discontinuations of study interventions and withdrawal from the study  should be 
documented with the prefix “COVI D-19- related” in the CRF.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 108
Approved , Date: [ADDRESS_493850] 2020Other relevant study  data elements impacted by [CONTACT_25963] -19 pandemic should also be 
documented/labeled as “COVID -19-related” in CRFs and/or other study  systems, as directed by 
[CONTACT_393428]; these may include missed/delay ed/modified study  visits/assessments/dosing, 
and instances where temporary measures such as those above are implemented.
Where applicable, other study  procedures may be conducted at an appropriate facility  identified 
by [CONTACT_4145].
Study Analyses
The Sponsor will evaluate the totality of impact of COVID -19 on collection of key study data and 
additional data anal yses will be outlined in the statistical analy sis plan(s).
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 109
Approved , Date: [ADDRESS_493851] 202011. REFERENCES
1. Adalimumab SmPC.
2. Adedokun OJ, Zhenhua X, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao L -L, Davis H, Hanuauer S, 
Fegan BG, Ghosh S Sandborn WJ. Pharmacokinetics and Exposure -Response Relationships of Ustekinumab in 
Patients with Crohn's Disease. Gastroenterology. 2018; https://doi.org/10.1053/j.gastro.2018.01.043.
3. Amiot A, Serrero M, Peyrin -Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang -
Poisson C, Altwegg R, Marteau P, Vaysse T, Bourr ier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, 
Vuitton L, Viennot S, Aubourg A, Pelletier A -L, Bouguen G, Abitbol V, Gagniere C, Bouhnik Y. Alimentary 
Pharm acology and Therapeutics. 2017; 46:[ADDRESS_493852] WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National 
Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70(3):439 -444.
5. Certolizumab US PI.
6. Claire, P, Severine, B, Nicolas, D, Nicolas D, Maria N, Pi[INVESTIGATOR_11958] D, Julien B, Romain G, Medina B, Myriam L,
Benjamin P. Trough levels and antibodies to ustekinumab are not correlated to response to ustekinumab 
treatment in Crohn's disease patients. ECCO 2017 #P360.
7. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative 
colitis than in Crohn’s disease. Gut. 2005; 54:364 -368.
8. D’Haens GR, Panaccione R, Higgins P, Vermeire S, Gassull M, Chowers Y, Hanauer S, Herfarth H, Hommes 
D, Kamm M, Lofberg , R, Quary A, Sands B, Sood A, Watermayer G, Lashner B, Lemann M, Plevy S, 
Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel J -F, Travis S. 
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD 
with the European Crohn’s and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and 
How  to Predict Respsnse. American Journal of Gastroenterology. 2011;106, 199 -212.
9. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao L -L, 
Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel J -F, 
Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus Jr EF, Dieleman LA, Katz S, Rut geerts P. 
Ustekinumab as Induction and Maintenance. Therapy for Crohn’s Disease. NEJM. 2016;375:1946 -60. Online 
Supplement.
10. Feagan BG, Sandborn WJ, Gasink C, Group U -I-US, et al. Ustekinumab as induction and maintenance therapy 
for Crohn’s Disease. N Engl J Med. 2016;375:1946 –1960.
11. Gom ollón F, Dignass A, Annese V et al. Journal of Crohn’s and Colitis. 3rdEuropean Evidence -based 
Consensus on the GTiagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical 
Management. 2017;3 -25.
12. Heron V, Restellini S, Bessissow  T, Lemieux C, Lakatos P, Wild G, Seidman E, Bitton A, Afif W. Re -
induction with ustekinumab in Crohn’s disease patients with a loss of response to treatment. ECCO [ADDRESS_493853] 438.
13. Infliximab SmPC.
14. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the 
treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. 
Gastroenterology. 1994;106(2):[ADDRESS_493854] D, Marín -Jiménez I, Chaparro M, Sierra Monica, Aguas M, Sicilia B, Garcia -Sanchez V, 
Suarez C, Villoria A, Taxonera C, Velasco -Guardado An, Martinez -Gonzalez J, Gisbert JP. Ustekinumab for 
the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicen tre Open -label 
Cohort. Inflamm Bow el Dis. 2016 Jul;22(7):1662 -9.
16. Kopylov U, Afif W, Cohen A, Bitton A, Wild G, Bessissow  T, Wy se J, Al -Taweel T, Szilagyi A, Seidman E. 
Subcutaneous ustekinumab for the treatment of anti -TNF resistant Crohn's disease --the Mc Gill experience. J 
Crohn’s Colitis. 2014 Nov;8(11):1516 -22.
17. Lichtenstein GR et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J 
Gastroenterol. 2018 Mar;113(4):481 -517.
STELARA (ustekinumab)
Clinical Protocol CNTO1275CRD3008 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 110
Approved , Date: [ADDRESS_493855] 202018. Ma, C, Fedoera RN, Kaplan G, Dieleman LA, Devlin SM, Stern N, K roeker KI, Seow  CH, Leung Y, Novak 
KL, Halloran BP, Huang VW, Wong K, Blustein PK, Ghosh S, Panaccione R. Long -term Maintenance of 
Clinical, Endoscopic and Radiographic Response to Ustekinimab in moderate -to-Server Crohn’s Diease: Real -
world Experience fro m a Multicenter Cohort Study. Inflammatory Bowel Disease. 2017. DOI 
10.1097/MIB.0000000000001074.
19. Park S, Evans E, Sandborn WJ, Boland B. Ustekinumab IV 6 mg/kg Loading Dose Re -induction Improves 
Clinical and Endoscopic Response in Crohn’s disease: A Case Series. American Journal of Gastroenterology. 
2018; 113:627 -629.
20. Qiu Y, Chen B -L, Mao R, Zhang S -H, He Y, Zeng Z -R, Ben -Horin S, Chen M -H. Journal of Gastroenterology. 
2017;52:[ADDRESS_493856] OP010.
22. Sandborn WJ et al. Vedolizumab as inductio n and maintenance therapy for Crohn's disease. N. Engl. J. Med. 
2014;369(8):711 -721.
23. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, 
Rutgerrts PJ. Long -term Outcome of Treatment with Infliximab in 614 Crohn’s Disease Patients: Results from 
a Single Centre Cohort. Gut. 2008; doi:10.1136/gut.2008.155812.
24. Solem CA, Loftus EV, Tremaine WJ, et al. Correlation of C -reactive protein with clinical, endoscopic, 
histologic, and radiographic activity in inflammat ory bow el disease. Inflamm Bowel Dis. 2005;11(8):[ADDRESS_493857]. Anti -TNF -Re-
induction is as Effective, Simpler and Cheaper Compared with Dose Interval Shortening for Secondary Loss of
Response in Crohn’s Diseaes. Journal of Crohn’s and Colitis. 2017: doi:10.1093/ecco -jcc/jjx144.
26. Stallmach A, Langbein C, Atreya T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss 
JC, Schmelz R, Siegmund B, Schulze H, Teich N, van Arnim U, Baumgart CD, Schmidt C. Alimentary 
Pharm acology and Therapeutics. 2016; 44:1199 -1212.
27. STELARA [EU SmPC]. Beerse, Belgium: Janssen -Cilag International NV; 2016.
28. Summary of Clinical Pharmacology Studies, ustekinumab. Treatment of Adults with Moderately to Severely 
Active Crohn’s Disease. EDMS -ERI-92904905, 1.0. 2015.
29. Vedolizumab SmPC.
30. Verm eire S, Van Assche G, Rutgeerts P. C -reactive protein as a marker of inflammatory bowel disease. 
Inflamm Bow el Dis. 2004;10(5):661 -665.
31. Wils P, Bouhnik Y, Michetti P, Flo urie B, Brixi H, Bourrier A, Allez M, Duclos B, Grimaud J -C, Buisson A, 
Amiot A, Fumery M, Roblin X, Peryin -Biroulet L, Filippi J, Bougeuen G, Abitbol V. Subcutaneous 
Ustekinumab Provides Clinical Benefit for Tw o-Thirds of Patients With Crohn's Disease Ref ractory to Anti -
Tumor Necrosis Factor Agents. Clin Gastroenterol Hepatol. 2016 Feb;14(2):242 -50.e1 -2.
32. Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Serrero M, Buisson A, 
Amiot A, Fumery M, Roblin X, Peryin -Biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, 
Laharie D, Pariente G. Long -term efficacy and safety of ustekinumab in 122 refractory Crohn's disease 
patients: a multicentre experience. Aliment Pharmacol Ther. 2018 Jan 8. [Epub ahead of print].